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Abstract
The human brain undergoes a prolonged maturation period in which cells
follow carefully choreographed, cell type-specific developmental trajectories
that interweave with those of neighboring cells. Regulation of these develop-
mental programs is influenced both by genetics and environment, and can
be interpreted via changes to the transcriptome and epigenome. Profiling
these aspects of human brain biology in normal development can potentially
illuminate vulnerable timeframes and molecular mechanisms that go awry in
neurodevelopmental psychiatric diseases.
In chapter two, we examine the patterns of RNA compartmentalization
by the nuclear membrane in developing and mature human cortex to elu-
cidate the relationship between compartmentalization and developmental
gene expression patterns, and to probe the limits of the utility of single nu-
cleus RNA-sequencing projects derived from postmortem brain tissue. We
isolated nuclear and cytoplasmic RNA from three prenatal and three adult
homogenate cortical samples and performed RNA-sequencing using two li-
brary types. Using linear regression, we found that although many genes
are differentially expressed by fraction, developmental expression changes
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are similarly detectable in nuclear and cytoplasmic RNA. Differences in ex-
pression in prenatal RNA compartments were more muted than in adult;
higher nuclear expression was also associated with reduced expression in the
opposite age, suggesting a down-regulation of expression. Interestingly, we
found that nuclear-enriched genes were also preferentially enriched in gene
sets associated with neurodevelopmental psychiatric diseases.
To interrogate the epigenome, in chapter three we next characterized the
landscape of DNA methylation across human brain development in neurons
and glia using whole-genome bisulfite sequencing. We refined global pat-
terns of increasingly divergent neuronal CpG methylation (mCpG) and CpH
methylation (mCpH, where H=A, C, or T) into six unique developmental
trajectories. While mCpH levels were uncorrelated genome-wide, together
all methylated cytosines in the six trajectories showed similarly high auto-
correlation as mCpG levels alone. We lastly integrated paired RNA-seq data
and identified direct regulation of hundreds of transcripts and their splicing
events exclusively by mCpH, independent of mCpG levels, across the first
decades of human brain development.
These studies highlight the dynamic nature of human brain development
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The brain is more than an assemblage of autonomous modules, each
crucial for a specific mental function. Every one of these functionally
specialized areas must interact with dozens or hundreds of others, their
total integration creating something like a vastly complicated orchestra
with thousands of instruments, an orchestra that conducts itself, with an
ever-changing score and repertoire.
—Oliver Sacks
The brain holds a distinctive position in the hierarchy of human organs
both for being the seat of human experience—generating thought, emotion,
and personality, while managing the more base, unconscious functions of
other organs that maintain the body—but also for being so difficult to study.
It took 67 years after Theodor Schwann extended cell theory to animals for the
prevailing theory of the day—that the brain was a continuous network—to be
disproved. The cells of the brain are so numerous and intricately comingled
that although it was known that cells comprised the rest of the body, it was
hard to accept that what appeared as an unbroken reticulum was actually
made of individual units. In applying Golgi staining to brain, Santiago Ramón
y Cajal was first able to visualize the elaborate form of an individual neuron,
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establishing the inception of modern neuroscience (López-Munoz, Boya, and
Alamo, 2006).
In the intervening century, the field of neuroscience has made many ad-
vances in understanding this enigmatic organ, but there continues to be a
great distance to travel before we completely understand the regulation of
the genesis of the adult brain, the foundation of our humanity—and how
this goes awry when a person develops a psychiatric disease. One promising
avenue for interrogating these diseases’ origins is to interpret the influence of
the genetic code on the developmental trajectories that coalesce into a mature
functioning brain. In this chapter I elaborate on these concepts, as well as
provide an overview of the aims of this dissertation.
1.1 Human brain structure, composition,
and development
The brain is organized in a regional manner, where each region is associated
with a specific group of functions. This dissertation focuses on the cerebral
cortex, a 2-3 mm sheet of tissue that covers both hemispheres. Topographically,
the cerebral cortex is subdivided by regional functions such as vision, motor
control, and perception (Shipp, 2007). Of particular interest is the prefrontal
cortex, the most rostral subdivision of the cortex, which is associated with
higher cognitive functions such as decision-making and self-control, language,
emotional processing, and sociality (Teffer and Semendeferi, 2012). The dorso-
lateral prefrontal cortex (DLPFC) occupies Brodmann areas 9, 10 and 46 within
the prefrontal cortex and is associated especially with executive functions like
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working memory, synthesizing sensory input, attention, and goal-directed
behaviors (Teffer and Semendeferi, 2012). Because of the higher-order nature
of these functions, the DLPFC undergoes an extended maturation process that
continues into adulthood (Petanjek et al., 2011).
Radially, the cortex is organized into six layers, each characterized by
cells with distinct cytoarchitecture. The types of cells in the DLPFC are myr-
iad but can broadly be distinguished as neurons and glia, each representing
roughly 50% of cortical cells. Beyond this dichotomy, the diverse shapes,
electrophysiological properties, gene expression patterns, neurotransmitters,
location, and projections of these cells lead to an onerous explosion of po-
tential cell classes. In simplistic terms however, the main categories break
down to six types: pyramidal neurons, interneurons, oligodendrocytes, as-
trocytes, microglia, and endothelial cells. Pyramidal neurons, often referred
to as glutamatergic or projection neurons, are large cells that express gluta-
mate as their neurotransmitter and play an excitatory role in neuronal circuits.
They predominate the "deep" layers (5 and 6) of the cortex and have long
axons that project to other brain regions, such as the thalamus, spinal cord,
or other cortical areas (Leyva-Díaz and López-Bendito, 2013). Interneurons
are smaller cells that express GABA as their neurotransmitter and mostly act
to inhibit circuit activity. While GABAergic neurons represent around 20% of
cortical neurons, they are much more diverse as a group than their pyramidal
counterparts (Markram et al., 2004). Unlike pyramidal neurons, interneurons
are more abundant in layers two through four; also, interneuron axons do
not project out of the cortex into white matter but rather ramify around the
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cortical column or across neighboring columns, leading to a more local impact
on circuit function (Markram et al., 2004). Oligodendrocytes are glial cells
that produce myelin, a substance that ensheathes neuronal axons and insu-
lates their electrical signaling leading to more efficient conduction(Rowitch
and Kriegstein, 2010). Astrocytes are the most abundant cortical macroglia
and serve a variety of functions, from maintaining homeostasis of water and
ion distribution, maintaining the blood-brain barrier, providing structural
support, and participating in cell to cell signaling (Rowitch and Kriegstein,
2010). Finally, microglia are the class of macrophages that reside in brain and
are critical to early synapse pruning, maintaining homeostasis, and protect-
ing against pathogens (Matcovitch-Natan et al., 2016; Mariani and Kielian,
2009). Endothelial cells line the blood vessels in the brain and are critical in
maintaining the blood brain barrier (Joó, 1996).
The formation and composition of each layer is determined by a develop-
mental path and timeline unique to each cell type. Neurogenesis in humans
begins soon after the neural folds fuse to form the neural tube roughly four
weeks after conception (Silbereis et al., 2016). Excitatory pyramidal neurons
are born first in the dorsal pallium and migrate radially into the cortical
plate, the precursor to the cerebral cortex; inhibitory interneurons largely arise
ventral to these cells in the ganglionic eminence and follow tangentially to
the cortical plate (Silbereis et al., 2016). Laminar positioning originates in
a bottom-up formation according in part to birth order, where earlier-born
pyramidal neurons first settle layers five and six, then later neurons populate
4
the overhead layers (Silbereis et al., 2016). While this occurs, pyramidal neu-
rons help recruit specific interneuron subtypes to coexist in specific layers,
depending on the subtype of each pyramidal neuron (Lodato et al., 2011).
Neuronal expansion and migration continue throughout a prolonged window
beginning in embryonic development and lasting until shortly before birth
(Kang et al., 2011), although in some regions they last until age three (Silbereis
et al., 2016).
Gliagenesis commences after neurogenesis begins. Oligodendrocytes first
emerge in mid-gestation and continue to be generated extensively through
the first three years of life and at a slower rate through adulthood (Silbereis
et al., 2016). Astrogliogenesis also is thought to begin during mid-gestation
and continues through the first three years of postnatal life (Silbereis et al.,
2016). Interestingly, unlike neurons and the macroglia (oligodendrocytes
and astrocytes), microglia are derived from erythromyeloid progenitors that
migrate to the brain early in prenatal development (Prinz and Priller, 2014).
Once the blood-brain barrier is formed and microglia mature, they for the
most part rely on self-renewal to maintain their population (Matcovitch-Natan
et al., 2016).
Cell fate, laminar, and regional identity are dictated by specific transcrip-
tion factor gradients (Silbereis et al., 2016). Although oligodendrocytes and
astrocytes originate from radial glial cells that also give rise to neurons (Row-
itch and Kriegstein, 2010), these gradients lead to the divergent outcomes.
For example, excitatory pyramidal neurons can be specified from radial glia
via a transcription factor cascade including, Pax6, Tbr2, NeuroD, and Tbr1
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(Hevner et al., 2006). Interneurons from the medial ganglionic eminence are
shaped by a cascade beginning with Shh, then followed by Nkx2.1, Lhx6 and
Lhx8, and Sox6 (Kelsom and Lu, 2013). Oligodendrocyte lineage is established
with expression of PDGFR-α, SOX10 and NG2, while astrocytes are influenced
by the expression of ALDh1L1 (Rowitch and Kriegstein, 2010). Cell subtype
designation is further influenced by factors that specify cortical layer, such as
how Ctip2 specifies layer 5 location in neurons (Hevner, 2007). Knowledge
of these transcription factor cascades can help in identifying cell types and
stages in human postmortem brain tissue, as further discussed in section 1.5.
As these cells find their way to their locations and continue to mature, the
cortex undergoes an explosive period of forming connections. Thalamocortical
axons reach the cortex and neurons sustain frenzied dendritic arborization
and synaptogenesis beginning in late mid-fetal development; at this time,
the first evidence of electrical signaling occurs and the cortical plate begins
to resemble the characteristic six layers of the mature cortex (Silbereis et al.,
2016). This extensive connective proliferation continues through the first or
second year of life, depending on the cortical region, although the expansion
of pyramidal neuron size and arborization persists as a slower rate until age
five (Koenderink and Uylings, 1995). Myelination, meanwhile, begins to occur
in early postnatal life and continues throughout adulthood (Silbereis et al.,
2016).
Following the period of overproduction, the cortex undergoes extensive
and selective pruning beginning in adolescence and continuing to a lesser
extent into the third decade of life (Petanjek et al., 2011). The timing of
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maturation for different circuits are commensurate with the developmental
timing of the cognitive skills associated with their function; for instance,
humans do not fully develop executive functioning until the early adulthood,
commensurate with the slow maturation of the DLPFC (Petanjek et al., 2011).
Like the "vastly complicated orchestra" without a conductor that Oliver
Sacks described, the cells of the brain take on distinct roles within a maturing
circuit based on their lineage fate, creating an unfathomably complicated yet
intricately connected whole directed only by the sheet music of the genetic
code and audience participation from the environment. Throughout develop-
ment, the post-mitotic neuronal players apply their lifetime of experience and
genetic "muscle memory" to result in the unique symphony that is an adult
human brain.
1.2 Schizophrenia: A developmental brain disease
Given such a complicated system dependent on an unthinkable number of pro-
cesses occurring correctly, it is amazing to realize any human brain functions
as it should, particularly because these processes are influenced by individual
genetic differences and environmental happenstance. Depending on the tim-
ing and severity of a genetic or environmental insult, a brain can appear to
function normally until the perturbed circuitry is required. This is the case in
schizophrenia, an adult-onset neuropsychiatric disorder that afflicts 1% of the
world population (Birnbaum and Weinberger, 2017). The types of symptoms
of schizophrenia are threefold: positive symptoms such as psychosis, halluci-
nations and delusions; negative symptoms such as withdrawal or flat affect;
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and cognitive symptoms such as thought disorganization, memory issues,
and disruption of the executive functions described previously (Birnbaum
and Weinberger, 2017). Age of onset in males is in the early twenties, while in
females onset typically occurs in the late twenties to early thirties.
A schizophrenia diagnosis is an incredibly difficult burden both to an
individual and society. About 60% of schizophrenia cases are recurrent over
the lifetime (Barbato, 1996). The mortality rate of individuals diagnosed with
schizophrenia is at least twice that of the general population (Barbato, 1996).
On a societal scale, schizophrenia was named one of the top 25 most disabling
diseases globally in 2013; a meta-analysis of studies calculating the cost of
schizophrenia placed the annual rate between $94-102 billion, representing
0.02-1.65% of the gross domestic product (Chong et al., 2016).
Despite the adult age of onset, evidence from both genetics and envi-
ronmental studies implicate aberrant brain development in the etiology of
schizophrenia. Schizophrenia is a highly heritable disorder, with estimates of
heritability around 80% (Gejman, Sanders, and Duan, 2010). A large genome-
wide association study between schizophrenia cases and healthy controls iden-
tified 108 genomic loci containing common single nucleotide polymorphisms
(SNPs) that were associated with schizophrenia risk (Psychiatric Genomics
Consorium, 2014). Examining the expression of genes falling within these loci
showed that they were relatively enriched for expression in fetal compared
to postnatal DLPFC (Birnbaum et al., 2015). A complementary study of de
novo variants in schizophrenia patients found that genes containing these
variants formed a network of co-expression and protein interaction in fetal
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DLPFC, suggesting that cortical neurogenesis may be altered during gestation
in schizophrenia (Gulsuner et al., 2013).
Likewise, several early life experiences have been linked to schizophre-
nia development. Women whose mothers experienced severe nutritional
deficits during the first trimester of pregnancy had more than doubled odds of
developing schizophrenia in adulthood (Susser and Lin, 1992). Obstetric com-
plications have also been associated with developing schizophrenia (Cannon,
Jones, and Murray, 2002), as well as living in an urban environment (Vassos
et al., 2012). Interestingly, combining genetic and environmental risk factors
can greatly amplify schizophrenia risk. It was shown recently that polygenic
risk score, a metric measuring inheritance of the 108 risk-associated alleles
identified in the GWAS, was five times more predictive of schizophrenia di-
agnosis in individuals that had experienced early life complications during
pregnancy, labor, or delivery (Ursini et al., 2018).
Although the incrimination of developmental processes in schizophrenia
risk is now clear, the specific neuropathology or molecular mechanisms are
not yet well understood. Several developmental trajectories have been impli-
cated, and due to the phenotypic heterogeneity of schizophrenia it is likely
that each may play a role. For instance, neural oscillations particularly in
the beta- and gamma-band frequency are abnormal in schizophrenia brains
(Uhlhaas and Singer, 2010). Gamma oscillations emerge late in development,
are associated with executive functioning, and are attributed to the activity of
fast-spiking parvalbumin interneurons in cortical layer 3 of the DLPFC (Lewis
et al., 2012). One hypothesis is that N-methyl-D-aspartic acid-type glutamate
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receptor (NMDAR) hypofunctioning in these interneurons leads to reduced
gamma-oscillation production; however, it is unclear if this imbalance is the
result of a primary reduction in interneuron inhibition, or a result of upstream
dysfunction in pyramidal neuron excitation (Nakazawa K1, 2012). Another
avenue of dysregulation leading to cognitive dysfunction in schizophrenia is
aberrant myelination, which can alter synaptic formation and function (Taka-
hashi et al., 2011). Several studies have found schizophrenia to be associated
with pathways related to myelination and oligodendrocyte function (Duncan
et al., 2014; Yu et al., 2014). Yet another line of evidence relates to the aberrant
synaptic pruning in adolescence characteristic of schizophrenia. Proper prun-
ing relies heavily on the activity of glial cells such as astrocytes and microglia
(Neniskyte and Gross, 2017). Recent work that identifies polymorphisms
within the C4 gene, a part of the complement immune system in the MHC
locus, as one of the strongest genetic associations with schizophrenia risk high-
lights the potential importance and vulnerability of these glia in schizophrenia
etiology (Sekar et al., 2016).
Given this aggregation of orthogonal evidence, further work to elucidate
the "when" and "where" of schizophrenia pathology in terms of brain de-
velopment is required, particularly in understanding how these competing
narratives of developmental perturbation fit together. It is worth noting that
the same principles that apply to schizophrenia here also apply to other neu-
rodevelopmental psychiatric disorders, such as autism spectrum disorder and
bipolar affective disorder—identifying the timing and affected cell type(s) of
a known genetic or environmental risk factor can illuminate the path forward
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for rectifying the altered developmental trajectory for many related disorders,
placing the brain back on a healthy path.
1.3 Regulatory mechanisms of brain development
What are the mechanisms that govern developmental decisions within a
cell? Fundamentally they begin with the genetic code in each cell and how
the code is utilized. The central dogma of molecular biology provides a
skeletal view of how this occurs: DNA is transcribed in the nucleus to mRNA,
which is exported to the cytoplasm and translated to a protein that performs
some cellular function. Further scrutiny drapes layers of nuance over these
bones. Non-coding RNAs such as miRNA and lncRNA, for example, are
not translated; rather, they can be a part of feedback loops regulating later
transcription or translation of other genes or transcripts, or act themselves
within the cell as signaling molecules, scaffolding structures, or regulators
of protein activity (Geisler and Coller, 2013; Schmiedel et al., 2015). Post-
transcriptional modifications such as alternative splicing and RNA editing
can also affect how and when a transcript is used, as well as the localization
of a transcript within the cell (see below). Finally, the epigenome regulates
DNA use by controlling DNA accessibility and factor recruitment, altering
if or how the DNA can be used (Perino and Veenstra, 2016; Thurman et
al., 2012). Profiling the transcriptome and epigenome is particularly useful
because both integrate genetic and environmental information and provide
means to interpret the functional readout of that information. This dissertation




Compartmentalization by the nuclear membrane is an often-overlooked mech-
anism of RNA regulation. In contrast to cytoplasmic RNA, the nuclear tran-
scriptome is populated by pre-mRNA, and aberrant and activity-dependent
transcripts that have been sequestered (Tilgner et al., 2012; Djebali et al., 2012;
Zaghlool et al., 2013; Solnestam et al., 2012; Pandya-Jones et al., 2013; Prasanth
et al., 2005; Mauger, Lemoine, and Scheiffele, 2016). A major role of the nu-
clear membrane is to act as a transcriptional noise buffer by filtering stochastic
bursts of gene expression from the cytoplasm (Halpern et al., 2015; Battich,
Stoeger, and Pelkmans, 2015).
Many of the mechanisms that regulate RNA localization across the nuclear
membrane are frequently used in brain cell lineages, and have been shown to
play a role in developmental programs. For instance, intron retention often
occurs in weakly expressed transcripts as a signal to the nuclear surveillance
machinery to sequester and degrade aberrant or superfluous transcription
products via the exosomes (Boutz, Bhutkar, and Sharp, 2015). In vitro neurons
as well as other cell types show increasing levels of intron retention as they dif-
ferentiate from induced pluripotent stem cells, principally in lowly expressed
genes involved in determining counter cell fates (Wong et al., 2013; Yap et al.,
2012; Braunschweig et al., 2013). Intron retention also can signal temporary
nuclear sequestration of activity-dependent transcripts in neurons (Mauger,
Lemoine, and Scheiffele, 2016). RNA editing, another post-transcriptional
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modification developmentally regulated in human brain that is especially
involved in neuronal maturation (Hwang et al., 2016), has also been shown
to regulate activity-dependent nuclear transcript retention, although RNA
editing does not seem to globally signal sequestration (Prasanth et al., 2005;
Chen, 2013).
1.3.2 DNA methylation
DNA methylation (DNAm), a major component of the epigenome, is the
covalent addition of a methyl group to the fifth carbon of a cytosine. The
methylated cytosine usually precedes a guanine (ie, CpG) but in some cell
types can be followed by another base (ie., CpH, where H=A, C or T) (Roden-
hiser and Mann, 2006).
mCpG is a stable modification that is faithfully copied from parent to
daughter cell during DNA replication by DNMT1 (Smith and Meissner, 2013),
although de novo methylation can be added via the methyltransferases DNMT3a
and DNMT3b (Feng et al., 2010). mCpG has historically been considered a
repressive mark, although this view is being upended as cannon (Rodenhiser
and Mann, 2006). In reality, the mCpG landscape reads more like a map to
be translated, where stereotyped mCpG features can be interpreted to signify
certain genomic conditions. In next generation sequencing data from a popu-
lation of cells, the ratio of methylated to unmethylated reads represents the
proportion of methylation at that cytosine across the population. In the mam-
malian genome, most CpGs are fully methylated (Stadler et al., 2011). Given
this relationship, previous work has identified several mCpG features that
13
correspond with known genomic outcomes. For example, short unmethylated
regions (UMRs) often correspond to promoter sequence because promoters
frequently contain CpG islands, clusters of rarely methylated CpGs (Stadler
et al., 2011). Low-methylated regions (LMRs), or short regions of less than
30% methylation, often correspond to active distal regulatory elements such
as enhancers (Stadler et al., 2011). Partially methylated domains (PMDs) are
long stretches of disordered mCpG levels that correspond with heterochro-
matin and polycomb repressed sequence (Lister et al., 2009). Finally, DNA
methylation valleys (DMVs) are longer regions of hypomethylation that cor-
respond to epigenetically regulated developmental genes. Although DMVs
are unmethylated, their chromatin profile reveals a bivalent state of both
activating H3K4me3 and repressing H3K27me3 signal (Xie et al., 2013). In
this way profiling the mCpG landscape can provide a picture of genomic
organization and activity in that population, although the causal relationship
between DNAm levels and genomic activity is not always clear. For instance,
although DNAm levels of transcription factor binding sites are reduced when
the factor is bound, suggesting a steric hindrance effect of DNAm on binding
(Stadler et al., 2011; Yin et al., 2017), actively transcribed gene bodies have
increased DNAm levels in most cell types (Laurent et al., 2010), and at least for
the typically methylation-sensitive transcription factor CTCF, in vivo removal
of DNAm does not alter CTCF binding (Maurano et al., 2015).
Neurons have the unique distinction along with embryonic stems cells
of having a high proportion of non-CpG methylation (mCpH) (Lister et al.,
2013). Unlike mCpG levels which are highly methylated, mCpH levels are
14
much lower due to the increased heterogeneity at each cytosine within each
population (He and Ecker, 2015). Unlike mCpG in other cell types (Laurent
et al., 2010), neuronal mCpH in gene bodies is anti-correlated with gene
expression and is only established de novo postnatally by DNMT3a during
neuronal development (Guo, Zhang, and Wu, 2016).
In terms of brain development, mCpG is a significant and early player,
maintaining prenatally-established global mCpG levels throughout the lifes-
pan; mCpH, on the other hand, increases rapidly from birth to early childhood
and then slowly accumulating into the twenties (Lister et al., 2013). How-
ever, because previous developmental studies have all been conducted in
homogenate tissue (Lister et al., 2013) or used microarray platforms that
lacked single base resolution (Jaffe et al., 2016), more definitive conclusions
cannot yet be drawn about the role of mCpH in neuronal maturation or the
relationship between mCpG and mCpH in developing neurons. It is known
however that changes to DNAm in both the CpG and CpH context occur
robustly in response to neuronal activity (Guo et al., 2011) and are critical to
learning and memory and the maintenance of synaptic plasticity (Halder et al.,
2016), suggesting that DNAm plays an integral role in the brain maturational
processes described in the previous section. Whether the driver or passenger
in establishing the epigenomic landscape, DNAm integrates the genetic and
environmental influences that have paved the developmental roads.
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1.4 Schizophrenia and brain development
regulation: What is known
Many studies have identified elements of schizophrenia risk reflected in the
transcriptome, particularly in terms of developmental shifts in risk gene
isoform expression. Two recent examples are risk-associated transcripts of
AS3MT and BORCS7 from the 10q24.32 locus (Li et al., 2016). A recent larger
study has found that almost half of the schizophrenia risk loci identified
in GWAS were expression quantitative trait loci (eQTLs) associated with
neighboring expression features, and that many of those neighboring fea-
tures included genes with shifting isoform expression across the prenatal to
postnatal transition (Jaffe et al., bioRxiv Preprint: April 5, 2017).
Although it is known that splicing can influence subcellular RNA localiza-
tion patterns, no studies to my knowledge have explored the role of nucleocy-
toplasmic RNA transport in schizophrenia or other developmental psychiatric
disorders. However, recent studies have highlighted the importance of proper
nucleocytoplasmic transport of proteins and RNA in the aging brain as well
as neurodegenerative disorders such as fronto-temporal dementia and amy-
otrophic lateral sclerosis (Mertens et al., 2013; Zhang et al., 2015). Namely, as
the brain ages, nuclear transport can become impaired in the brain.
In terms of DNAm and the epigenome, several studies have identified asso-
ciation between developmentally dynamic patterns of DNAm and schizophre-
nia risk. For example, two recent microarray-based DNAm studies—one in
fetal cortices and one in control cortices ranging from fetal to old age—found
that GWAS risk loci were enriched for being methylation quantitative trait
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loci (meQTL) (Jaffe et al., 2016; Hannon et al., 2016). Interestingly CpGs that
were differentially methylated between schizophrenic and control cortical
tissue were enriched for sites that were also differentially methylated between
prenatal and postnatal timepoints, but not between timepoints around the
schizophrenia age of onset, namely adolescence and early adulthood (Jaffe
et al., 2016). However, no studies to my knowledge have examined the rela-
tionship of schizophrenia risk with cell type-specific DNAm patterns at single
base resolution.
1.5 Technical considerations for working with
human postmortem brain
Given the human-specific nature of the affected organ in schizophrenia, and
the neoteny associated with the developmental trajectories of the affected
brain regions, it is critical to address the concepts presented above in studies
that use human postmortem brain as the substrate. Yet working with human
postmortem brain it is not without its unique challenges.
One challenge in designing experiments using human brain is addressing
the serious confounder of cellular heterogeneity. Previous work has shown
that cell type composition is one of the largest determinants of DNAm vari-
ability in studies that use homogenate tissue, and that age-associated DNAm
changes are highly confounded by cell type composition at individual CpGs
(Jaffe and Irizarry, 2014).
However, cells of the brain are not easily untangled, particularly after the
process of being flash frozen. Faced with this task, a researcher can empathize
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with the naysayers from the previous century, including Camillo Golgi, who
rebuffed the idea that the brain was made of individual cells at all.
Although there is no silver bullet, several options exist to address cellular
heterogeneity in postmortem human brain studies. Several reviews are now
available that summarize options in greater detail (Shin, Ming, and Song, 2014;
Varley et al., 2013), but I will highlight the three most popular here. The first
option is to use software that deconvolutes the homogenate signal based on
known cell type-specific profiles (Guintivano, Aryee, and Kaminsky, 2013;
Newman et al., 2016). This option is the most rapid and cost-effective option;
however, the results will only be an estimate from pooled DNAm or RNA
signal. It is worth noting also that using this type of strategy on RNA data will
estimate the proportion of the RNA represented by the given cell types, and
not the proportion of actual cells. This computational method also relies on
the existence of pure cell population references, which may not be available
for all cell types.
Another option is to perform laser micro-dissection (LCM), in which single
or groups of cells are excised with a laser from a thin tissue section (Rossner
et al., 2006). While LCM allows for the collection of the whole cell body,
the method suffers from low throughput, potentially poor RNA quality, and
higher levels of contamination.
Ultimately for this dissertation, we selected fluorescence-activated nuclear
sorting (FANS) to isolate cell types in a high throughput manner (Matevossian
and Akbarian, 2008). In addition to a higher yield, the multiple lasers of a flow
cytometer allow for multiparametric analysis that improves the yield purity
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and offers more flexibility in experimental design. The biggest distadvantage
to FANS, unfortunately, is that performing FANS on frozen postmortem brain
is too stressful on the tissue to isolate intact mature brain cells; therefore,
sorting must be done on purified nuclei, and any antibodies used must label
nuclear antigens.
While several groups have successfully used lineage-specific transcription
factors to isolate subtypes of neurons and glia (Kozlenkov et al., 2016; Okada
et al., 2011), most studies including recent single nuclei RNA-seq studies (Lake
et al., 2016; Lacar et al., 2016; Krishnaswami et al., 2016) isolate neurons from
non-neurons using an antibody that targets NeuN, a splice factor that is a
constitutive component of the neuronal nuclear matrix and a mature neuronal
marker (Sarnat, Nochlin, and Born, 1998; Dent et al., 2010; Kim, Adelstein,
and Kawamoto, 2009).
Another important caveat to this method is the potential for loss of im-
munoreactivity in postmortem brain tissue, even when using as robust an
antibody as the monoclonal anti-NeuN offered by Millipore Sigma (Catalog
#MAB377X). Previous work has shown that NeuN reactivity decreased in
mouse cortex following cerebral ischemia, but the number of neurons was
unaffected (Unal-Cevik et al., 2004). Similarly, NeuN reactivity was com-
pletely lost in the spinal cord of elderly rats, although the number of neurons
remained the same (Portiansky et al., 2006). These studies are reminders that
interpreting the absolute yield in terms of FANS-derived populations should
be undertaken with care. It is also worth noting that because FANS limits RNA
studies to the nuclear fraction, understanding the compositional differences
19
between RNA compartments over human brain development would help
inform future studies using nuclear RNA without a comparable cytoplasmic
fraction.
1.6 Research objectives and thesis summary
The overarching goal of this work was to use next-generation sequencing to
explore how the transcriptomes and epigenomes of human cortex and cortical
cells are developmentally regulated, in an attempt to clarify the "when" and
"where" of schizophrenia neuropathology in the context of schizophrenia
genetics.
In Chapter 2, we have isolated nuclear and cytoplasmic RNA from three
prenatal and three adult cortices and conducted RNA sequencing using two
different library preparation methods to explore developmental shifts in RNA
subcellular localization patterns and examine the distributions of gene sets
associated with neurodevelopmental, neurodegenerative, and psychiatric
disorders. We found that developmental differences in gene expression are
similarly detectable in nuclear and cytoplasmic RNA, despite many genes
being differentially expressed by fraction. Gene expression was much more
similar across fractions in prenatal than adult cortex, and expression patterns
suggested a down-regulation of some prenatally expressed genes in adult
via nuclear retention. Interestingly, nuclear-enriched genes in both prenatal
and adult cortex were enriched in psychiatric disorder gene sets, but not
neurodegenerative disorder gene sets, raising the intriguing possibility that
nucleocytoplasmic transport is related to neuropsychiatric disease etiology.
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In Chapter 3, we used whole genome bisulfite sequencing to character-
ize the landscape of DNA methylation across human brain development in
neurons and glia. In doing so, we improved the resolution of previous stud-
ies to identify six unique developmental trajectories of mCpG and mCpH.
We showed that even though neighboring mCpH levels were uncorrelated
genome-wide, within these trajectories, all methylated cytosines showed sim-
ilar autocorrelation as mCpG levels by themselves. Using paired RNA-seq
data, we were able to discern direct regulation of hundreds of transcripts
and their splicing events exclusively by mCpH, outside the context of mCpG,
across postnatal brain development. These DNAm trajectories and splicing-
associated mCpHs were also enriched for gene sets associated with neuropsy-
chiatric disease, providing insight into the putative timing and affected cell
type for the dynamically methylated neuropsychiatric disease genes, and a
new understanding of the role of CpH methylation in gene expression.
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Chapter 2
Characterizing the nuclear and
cytoplasmic transcriptomes in
developing and mature human
cortex uncovers a potential new
avenue for psychiatric disease gene
dysregulation
2.1 Abstract
The diverse functions of transcriptome compartmentalization by the nuclear
membrane are enacted via mechanisms such as intron retention and RNA
editing that are used frequently in brain and are involved in development.
Comparing RNA fractions in brain can also inform the limits of what can
be learned from single nucleus RNA-sequencing projects derived from post-
mortem brain tissue. To examine the relationship between RNA compartmen-
talization and development in human postmortem cortex, we isolated nuclear
and cytoplasmic RNA from prenatal and adult homogenate cortical samples
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and performed RNA-sequencing using two library preparations. We find that
although many genes are differentially expressed by fraction, developmental
expression changes are similarly detectable in nuclear and cytoplasmic RNA.
Across ages, RNA fractions were more similar in prenatal than adult cortex,
and higher nuclear expression was associated with reduced expression in the
opposite age. Intron retention was overall greater in nuclear RNA; surpris-
ingly, genes containing differentially retained individual introns by fraction in
one age were higher expressed in that age. We confirmed that RNA editing
was not globally associated with RNA fraction expression, although genes
containing sites unique to a compartment in one age were higher expressed in
those samples. Finally, we found that nuclear-enriched genes were also prefer-
entially enriched in gene sets associated with neurodevelopmental psychiatric
diseases.
2.2 Introduction
Human brain development is characterized by precisely-timed changes to
gene expression across the lifespan, particularly at the prenatal to postnatal
transition (Kang et al., 2011; Colantuoni et al., 2011; Jaffe et al., 2015). One
mechanism by which these changes are regulated is via the compartmental-
ization of the transcriptome by the nuclear membrane. Taking a snapshot of
the composition of each RNA compartment captures factors of both chance
and purpose at work: for instance, since most splicing of pre-mRNA occurs
co-transcriptionally in the nucleus (Tilgner et al., 2012; Djebali et al., 2012), pre-
mRNA and longer genes that take more time to be transcribed and exported
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are often overrepresented in the nucleus compared to cytoplasm (Zaghlool
et al., 2013; Solnestam et al., 2012; Pandya-Jones et al., 2013). Recent studies
have also highlighted the role of the nuclear membrane as a transcriptional
noise buffer, filtering stochastic bursts of gene expression from the cytoplasm
by retaining mature mRNA transcripts in the nucleus (Halpern et al., 2015;
Battich, Stoeger, and Pelkmans, 2015). Still, nuclear retention can also regu-
late the timing of cytoplasmic activity of a transcript (Prasanth et al., 2005;
Mauger, Lemoine, and Scheiffele, 2016) as well as perform quality control
by sequestering aberrant transcripts in the nucleus and targeting them for
degradation.
The mechanisms by which RNA import and export decisions are made
across the nuclear membrane are myriad and an area of active research. Inter-
estingly, many of these RNA trafficking mechanisms are particularly prevalent
in brain, and have been shown to play a role in development. For example,
alternative splicing—particularly intron retention—has been shown to reg-
ulate RNA localization as a means to suppress lowly expressed transcripts
via sequestration by nuclear surveillance machinery followed by exosome
degradation, or via nonsense mediated decay (NMD) in the cytoplasm (Boutz,
Bhutkar, and Sharp, 2015; Braunschweig et al., 2014). Intron retention is highly
prevalent in neuronal lineages and serves to down-regulate genes involved
in other lineage fates during neuronal differentiation (Wong et al., 2013; Yap
et al., 2012; Braunschweig et al., 2013). RNA editing has also been shown
to be developmentally regulated in human brain, with a subset of editing
sites associated with neuronal maturation (Hwang et al., 2016). In at least one
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example RNA editing has also been shown to regulate activity-dependent
nuclear transcript retention, although global characterization of RNA editing
patterns by subcellular fraction shows RNA editing not to be broadly neces-
sary for nuclear retention (Prasanth et al., 2005; Chen, 2013). Recent studies
have also shown that disruption of proper nucleocytoplasmic transport of
proteins and RNA plays a role in aging as well as neurodegenerative disorders
such as fronto-temporal dementia and amyotrophic lateral sclerosis (Mertens
et al., 2013; Zhang et al., 2015). Given this accumulation of evidence, subcel-
lular RNA localization may therefore play an underappreciated role in the
etiology of developmental brain disorders. Although nuclear and cytoplasmic
transcriptomes have been assessed using in vitro models, subcellular fractions
have not yet been characterized in cortical brain tissue.
Characterizing the nuclear and cytoplasmic RNA fractions in human brain
has additional relevance given the increasingly frequent use of nuclear RNA in
single cell and cell population-based studies of human brain (Lake et al., 2016;
Lacar et al., 2016). Because frozen post-mortem brain tissue is difficult to dis-
sociate to a single cell suspension, most protocols instead isolate nuclei, which
are more robust to degradation (Krishnaswami et al., 2016). Because these
protocols limit RNA studies to the nuclear fraction, understanding the compo-
sitional differences between compartments over human brain development
would help inform future studies using nuclear RNA without a comparable
cytoplasmic fraction.
To address these questions in human cortical tissue, we characterized the
nuclear and cytoplasmic transcriptomes in developing and mature prefrontal
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cortex using two RNA sequencing library preparation methods and examined
distributions of gene sets associated with neurodevelopmental, neurodegen-
erative, and psychiatric disorders. We show that although many genes are
differentially expressed by fraction, developmental differences in gene expres-
sion are similarly detectable in nuclear and cytoplasmic RNA. Interestingly,
gene expression was much more similar across fractions in prenatal than
adult cortex, and expression patterns suggested a down-regulation poten-
tially via nuclear retention of some prenatally expressed genes in adult. We
also explored potential mechanisms of gene expression regulation by frac-
tion and found that while intron retention was overall greater in the nuclear
compartment, introns that were significantly preferentially retained in adult
nuclear RNA were actually associated with higher expression in adult cortex.
RNA editing was confirmed not to be globally associated with RNA localiza-
tion, although editing sites unique to a compartment in a specific age were
associated with higher expression in that compartment. Finally, we found
nuclear-enriched genes in both prenatal and adult cortex to be enriched in
psychiatric disorder gene sets.
2.3 Results
As described in Figure S1, we sequenced nuclear and cytoplasmic RNA iso-
lated from three prenatal and three adult human brains. Because total RNA
from a given sample is dominated by rRNA, different strategies can be em-
ployed to improve the signal of other RNA species in the sequencing data (Li
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et al., 2014; Sultan et al., 2014; Cui et al., 2010). "PolyA" library preparation se-
lects polyadenylated transcripts via a pull-down step, while "Ribozero" library
preparation relies on a rRNA depletion step. Together, these library methods
capture the transcriptomic diversity in these subcellular compartments in
developing human brain because of their respective preferences for mature
mRNA and unpolyadenylated transcripts (e.g., ncRNA or pre-mRNA), as
seen in Fig. S2A. One adult nuclear "Ribozero" sample failed quality control
and was discarded. Demographic and sequencing information can be found
in Table S1. Two prenatal cytoplasmic "PolyA" samples had higher read depth
and were downsampled to a comparable depth. In total 43,610 ensembl genes
were expressed across samples.
The quality of fractionation was confirmed by determining that genes
known to localize either to the nucleus (i.e., MALAT1) or cytoplasm (i.e., ACTB,
FMR1) were significantly enriched in the appropriate compartment (False Dis-
covery Rate (FDR)<0.01; Fig. S2B), although prenatal samples showed less
enrichment than adult (FDR=1.2e-6 and FDR=9.6e-9 for ACTB and emph-
MALAT1 in adult, versus FDR=0.17 and FDR=0.44 in prenatal, respectively).
2.3.1 Developmental gene expression changes in human
cortex are similarly detectable in nuclear and cytoplas-
mic RNA
We first defined the RNA content differences between subcellular fractions and
replicated many characteristics that have previously been described (Tilgner
et al., 2012; Djebali et al., 2012; Zaghlool et al., 2013; Solnestam et al., 2012;
Halpern et al., 2015; Reddy et al., 2017; Bhatt et al., 2012). Genes that are
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significantly more abundant in the nucleus were overall longer than genes
more abundant in the cytoplasm, perhaps due to the longer temporal require-
ment for transcription and passive diffusion through the nuclear pore (Fig.
S2C). The proportion of reads aligning to introns was greater in the nucleus
than the cytoplasm in both PolyA and Ribozero samples (t>4.7, FDR≤5.96e-3),
indicating a greater proportion of immature pre-mRNA transcripts (Fig. S2D).
Because Ribozero libraries do not require polyadenylation for sequencing,
a greater proportion of differentially expressed genes were non-coding in
Ribozero samples (Fig. S3A-B). Genes significantly greater expressed in the
nuclear compartment in both adult and prenatal cortex were associated with
GTPase binding and protein serine/threonine kinase activity (FDR≤0.05).
However, expression patterns were overall similar between fractions at the
gene level. Principal component analysis showed that sample age and library
type were the largest contributors to transcriptomic variation, explaining 53%
and 35% of the variance (Fig. 1A). Assessing developmental changes in both
fractions identified similar numbers of differentially expressed genes (Fig.
1B). Developmental expression trajectories were highly correlated between
the fractions (ρ=0.89, t=335.8, p<2.2e-16; Fig. 1C), and 41-63% of significantly
regulated genes overlapped in the four groups (Fig. 1D).
2.3.2 Prenatal and adult human cortex show distinct patterns
of RNA localization across the nuclear membrane
We next examined the relationship between developmental stage and gene
expression by fraction and found that prenatal and adult cortex exhibited
unique RNA localization patterns across the nuclear membrane. We identified
38
1,892-1,894 genes differentially expressed by fraction in adult cortex, but only
30-40 genes differentially expressed in prenatal cortex (Fig. 2A, abs(Log2
Fold Change (LFC))≥1; FDR≤0.05). This localization pattern difference was
also seen in Ribozero samples (Fig. S3C-D). Interestingly, most differentially
expressed genes in prenatal samples were more abundant in the nuclear
compartment. Despite fewer genes being differentially expressed by fraction
in prenatal cortex, subcellular expression patterns were correlated between
prenatal and adult (ρ=0.60, t=125.9, p<2.2e-16; Fig. 2B). Although a larger
proportion of genes enriched in the nuclear fraction were non-coding than
those enriched in the cytoplasm (OR=0.25, p=2.2e-16), the majority (83.5%) of
all fraction-regulated genes were protein coding (Fig. 2C).
We then examined the relationship between developmental expression
trajectories in groups of genes differentially expressed by fraction and found
that the association of fraction expression with developmental expression
depended on the fraction in which the developmental changes were measured
(Fig. 2D). When measured in cytoplasmic RNA, nuclear-enriched genes in
adult cortex had enriched expression in prenatal cortex compared to adult
(OR=1.32, FDR=0.013), suggesting that perhaps these RNA products were
being sequestered in the nucleus in adult cortex. Cytoplasm-enriched genes in
adult cortex, on the other hand, were depleted in prenatal compared to adult
(OR=0.44, FDR=1.4e-18). When measured in nuclear RNA, however, nuclear-
enriched genes in adult cortex were significantly depleted in prenatal and
enriched in adult cortex (FDR=2.01e-10, OR=0.51), and cytoplasm-enriched
genes in adult were neither enriched nor depleted by developmental stage
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(FDR=1.0, OR=1.02).
Assessing age-associated expression differences in nuclear and cytoplasmic
RNA revealed a complementary perspective to the developmental regulation
of transcription by subcellular fraction. Genes with increasing and decreasing
developmental trajectories when measured in both fractions were on aver-
age higher expressed in cytoplasm (Fig. 2E). Interestingly, in adult cortex,
genes with developmentally decreasing expression (i.e., greater expression
in prenatal than adult cortex) when measured in cytoplasmic but not nuclear
RNA were more likely to be higher expressed in nucleus (OR=38.0, FDR=1.9e-
20), while those in nuclear but not cytoplasmic RNA were less expressed
in nucleus (OR=0.071, FDR=1.7e-10). Likewise, developmentally increasing
genes (i.e., greater expression in adult than prenatal cortex) when measured
in cytoplasmic RNA were less expressed in nucleus in adult cortex (OR=0.038,
FDR=4.7e-24), while those measured in nuclear RNA were more likely to be
greater expressed in nucleus than cytoplasm (OR=19.3, FDR=5.5e-10). Taken
together, these patterns suggest an inverted relationship between developmen-
tal gene expression changes and subcellular compartment RNA localization
in that down-regulated genes are more abundant in the nuclear compartment.
2.3.3 Intron retention patterns in prenatal and adult human
cortex associate with mRNA distribution
Because alternative splicing - particularly intron retention - has been impli-
cated as a mechanism of localization of transcripts within the cell (Boutz,
Bhutkar, and Sharp, 2015; Braunschweig et al., 2014) and can play a role in
regulating developmental gene expression (Wong et al., 2013; Yap et al., 2012),
40
we characterized alternative splicing across the PolyA samples. Unlike in the
Ribozero samples, in which the proportion of reads spanning splice junctions
was lower in the nuclear than cytoplasmic fraction (t=-4.3, FDR=0.016), the
proportion of splice junctions was not significantly different in PolyA samples,
as pre-mRNAs were depleted by polyA-selection (t=-1.0, FDR=0.344; Fig. 3A).
All following splicing analyses were therefore done using the PolyA samples.
Across all samples, skipped exons (SE) and intron retention (IR) repre-
sented the greatest percent of unique splice variants identified (22.7% and
28.1%, respectively; Fig. S4A). 42.8% more unique splice variants were iden-
tified in nuclear than cytoplasmic RNA, and 72.9% more in prenatal than
adult cortex (Fig. S4B). This is in agreement with prenatal cortex showing a
higher proportion of splice junctions than adult cortex (Fig. 3A). As in gene-
level expression, far fewer splicing variants were significantly differentially
expressed by fraction in prenatal compared to adult (Fig. S4C). Comparing
splice variant expression by age in both nuclear and cytoplasmic RNA, on the
other hand, showed the distribution of differentially spliced variant types to
be more similar to the overall proportion of each type (Fig. S4C).
Whether a splice variant was more expressed in nuclear than cytoplas-
mic RNA, or in prenatal than adult RNA, related to its variant type (Fig.
S4D). For instance, significantly differentially expressed IR events by fraction
(FDR≤0.05) were more likely to be higher expressed in the nucleus (OR=50.9,
FDR=8.7e-96), while SE and distal alternative 5’ exon start site (A5SS.D) and
3’ exon start site (A3SS.D) events were more likely to be higher expressed in
the cytoplasm (OR=0.091, FDR<1.7e-07). Comparing splicing patterns by age
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showed that in the cytoplasm, SE, IR, and proximal alternative 3’ start site
(A3SS.P) events were more abundant in prenatal than adult cortex (OR>2.3,
FDR<2.3e-05). In the nuclear compartment however, IR and A3SS.P events
were more abundant in adult than prenatal cortex (OR<0.69, FDR<2.2e-02).
To delve more deeply into IR patterns by fraction and age, introns were
filtered to exclude those that overlapped a known exon or were near a known
antisense transcript, those with non-uniform intronic coverage, and those with
less than four reads spanning a splice junction involving one of the two exon-
intron boundaries or less than four reads supporting intron inclusion at the
exon-intron boundaries. After filtering, 166,661-173,125 introns remained per
sample, representing 15,345-15,389 unique genes (Fig. S5A). 152,432 introns
were shared between all samples. Across samples, 58.68-85.33% introns were
constitutively spliced, and 12.20-34.63% had an IR ratio (i.e., intronic reads
divided by total intron and flanking exon reads) of greater than zero but less
than five percent. Overall, introns in nuclear samples had greater IR ratios than
cytoplasmic samples (t=69.5, FDR=0; Fig. 3B). Interestingly, although adult
samples overall had greater IR ratios than prenatal samples (t=15.9, FDR=3.7e-
56), this differed by fraction: IR was greater in adult samples in nuclear RNA
(t=25.9, FDR=1.2e-147), but greater in prenatal samples in cytoplasmic RNA
(t= -7.121, FDR=3.2e-12).
We next looked into the relationship between RNA subcellular localization
and IR by assigning the maximum IR ratio per sample for each gene with at
least one intron passing filtering parameters. Genes with significantly higher
expression in nuclear RNA in both adult and prenatal samples (FDR≤0.05)
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had overall higher IR ratios than genes enriched in the cytoplasm (t>17.7,
FDR<1.8E-65; Fig. 3C). Similarly, genes containing introns with greater than
10% retention were more likely to be significantly enriched in nuclear than
cytoplasmic RNA (FDR≤0.05; OR=1.7, FDR=1.7e-5; Fig. 3D). In terms of devel-
opmental expression trajectories, similar to above, developmental IR patterns
in cytoplasmic and nuclear RNA showed opposite relationships: measured in
the cytoplasm, genes with developmentally decreasing expression (FDR≤0.05)
had overall higher IR ratios (t=7.63, FDR<3.3e-14), while in the nucleus, genes
with increasing expression (FDR≤0.05) had overall higher IR ratios (t=-10.5,
FDR<3.4e-25; Fig. S5B). Likewise, genes containing introns with greater than
10% retention were more likely to be significantly enriched in adult than pre-
natal when measured in nuclear RNA (FDR≤0.05; OR=1.4, FDR=2.1e-7), but
depleted in adult when measured in cytoplasmic RNA (FDR≤0.05; OR=1.4,
FDR=2.1e-7; Fig. S5C).
We then measured differential retention of individual introns using the
Audic and Claverie test and identified 35 significantly differentially retained
introns (dIRs) by fraction in adult and 6 in prenatal cortex; across developmen-
tal stages, we identified 10 dIRs in cytoplasmic RNA and 21 in nuclear RNA
(FDR≤0.05, Fig. 3E). dIRs tended to be single rather than clustered within
a gene (90.4%), and were significantly shorter than the pool of total introns
tested (t<-32.8, FDR<2.2e-25). dIRs more retained in the nuclear compartment
were less conserved than the pool of total introns tested (t=-3.4, FDR=6.6e-
3) and less likely to contain repetitive elements (OR=0.034, FDR=1.04e-15).
Repeats were also depleted in dIRs that were more retained during prenatal
43
development than during adulthood (OR=0.11, FDR=5.0e-06). Locations of
dIRs by fraction across the length of the gene were bimodally distributed,
while dIRs more retained in adult than prenatal cortex were significantly
closer to the 5’ end of the transcript (t=5.06, FDR=1.5e-05, Fig. S5D).
Examining the expression patterns of genes including dIRs provided in-
sight into the relationship between fraction localization and cortical devel-
opment. Namely, genes including dIRs by fraction were more likely also to
include dIRs by age (OR=88.4, FDR=6.5e-04). Developmental dIRs were also
more likely to be in genes that were significantly differentially expressed by
fraction and vice versa (OR>2.8, FDR<0.032). Interestingly however, the rela-
tionship between dIRs and expression was the opposite as expected: nuclear-
increasing dIRs in adult cortex were depleted in prenatal-enriched genes
(OR<0.30, FDR<0.005; Fig. 3F).
2.3.4 Highly edited genes contain RNA editing sites unique
to an age/fraction group and are higher expressed in
that group
We next profiled RNA editing across subcellular fractions in prenatal and
adult cortex. We identified 3,064-5,840 editing sites per sample, finding 25,051
unique sites across the dataset. Of these, 75.5% were A-to-I edited sites, the
most common editing pattern (Appears as A:G or T:C in our sequencing data;
Fig. 4A). Of the A-to-I edited sites, 1,025 were shared by all four groups (Fig.
4B). Read coverage was fairly even over all samples at edited sites, with a
median coverage of 11-12 reads per site across samples (Fig. S6A). In line
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with previous reports, annotating the A-to-I editing sites showed that 21.7-
33.8% fell within intronic sequence and 37.6-50.8% within 3’UTR sequence by
group (Fig. S6B). 40.0-42.0% of A-to-I editing sites overlapped an Alu repeat
sequence (Fig. S6C). For all following analyses, we focused on the A-to-I sites.
We compared our editing sites to sites identified in other publications
and found that 69% of our 18,907 A-to-I editing sites were also detected by
the Genotype-Tissue Expression (GTEx) project30 (Fig. S6D). The largest
proportion of editing sites (46.3%) was found in brain compared to other
tissues in GTEX (Fig. S6E). 13.8% more novel sites were detected in prenatal
cortex than adult cortex, while 43.1% more novel sites were detected in nuclear
than cytoplasmic RNA.
To assess the relationship between subcellular localization and age in RNA
editing, we first assessed editing rate changes across fraction and age in the
1,025 sites shared among the four groups. As shown in Fig. S6F, the distri-
bution of unadjusted p-values suggested that age but not fraction influenced
editing rates. After adjusting for false discovery rate, 81 sites were associated
with age, while only 9 were associated with fraction and 6 with interaction
between age and fraction. Examining the subcellular localization patterns of a
subset of 742 editing sites identified in Hwang et al. (2016) that was increas-
ingly edited in human DLPFC as the brain matured showed that of the 576
identified in our dataset, sites detected in adult but not prenatal cortex were
more likely to be developmentally increasingly edited (OR=13.5, FDR=2.5e-
25). Increasingly edited sites from Hwang et al (2016) were significantly more
edited in adult than prenatal cortex (t=12.6, FDR=6.4e-34).
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Because most editing sites were found in only one group, we next focused
on the unique sites found in all samples of a group. The numbers of A-to-I
editing sites unique to each group and found in all samples in the group are
summarized in Fig. 4C. Genes containing an editing site in this subset were
highly edited, containing significantly more sites than other genes (t>3.25,
FDR<0.0069).
As with intron retention, presence of these editing sites also was associated
with gene expression. For instance, genes that were significantly greater
expressed in adult cortex were enriched for editing sites unique to and present
in all adult samples (OR=8.9, FDR=6.3e-19), while genes that were significantly
greater expressed in prenatal cortex were enriched for editing sites unique to
and present in all prenatal samples (OR=25.9, FDR=2.1e-26, Fig. 4D). These
prenatal editing site genes were also enriched for ribosomes in KEGG pathway
analysis (FDR=0.044). In both adult and prenatal cortex, editing sites that were
found in all nuclear but no cytoplasmic samples were more likely to occur
in genes that were significantly higher expressed in nuclear RNA than other
editing sites (OR>2.9, FDR<2.3e-02, Fig. 4E). Relatedly, annotation of these
fraction-associated sites showed that editing sites unique to and in all adult
cytoplasmic RNA samples were depleted for intronic (OR=0.169, FDR=0.0098)
and enriched for 3’UTR sequence compared to sites in adult nuclear RNA
(OR=3.96, FDR=0.0098). In all groups, 63-100% of edited 3’UTRs were from
the major isoform (Fig. S6G). Interestingly, although these editing sites were
found exclusively in one group, 86.49-100% of edited introns and 96.55-100%
of edited exons were expressed in other groups that do not have the edited
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site.
Because editing sites may disrupt RNA binding protein (RBP) binding, we
also examined the enrichment of RBP motifs overlapping editing sites using
RBPMap (Paz et al., 2014). Although no RBPs were enriched or depleted for
the groups of unique editing sites in Fig. 4C, 94 of the 114 RBP motifs tested
significantly overlapped an A-to-I editing site (FDR<0.05, Fig. S6H). RBP motif
enrichment varied by the annotation of the editing site: while editing sites in
CDS and 5’UTR were depleted for RBP motifs (OR>3.4, FDR<5.6e-41), editing
sites in introns were enriched for overlapping motifs of SRSF5, G3BP2, and
LIN28A (OR>1.2, FDR<3.08e-02), and editing sites in 3’UTRs were enriched
for SRSF3, IGF2BP2, IGF2BP3, and FMR1 (OR>1.15, FDR<4.5e-2). SRSF5
and SRSF3 are splicing factors that are part of the spliceosome; LIN28A is a
developmentally associated RBP, while IGF2BP2 and IGF2BP3 are associated
with regulating the translation of IGF2 (RefSeq). FMR1, best known for its
role in fragile X mental retardation, is also thought to modulate trafficking
of mRNA across the nuclear membrane from the nucleus to the cytoplasm
(RefSeq).
2.3.5 Genes differentially expressed by fraction are
overrepresented in gene sets associated with psychiatric
disease
We finally performed Disease Ontology (DO) Semantic and Enrichment anal-
ysis on the sets of genes differentially expressed by fraction and age. Genes
with a significant interaction between subcellular localization and age were
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enriched for involvement in Alzheimer’s disease and other neurodegenera-
tive diseases (abs(LFC)≥1; FDR≤0.05; Fig. S7A). Since the subcellular com-
partments are globally more similar in prenatal than adult samples, many
of these genes were more highly expressed in adult than prenatal cortex,
with greater expression in adult cytoplasm compared to nucleus. ALDH2
is an example of this expression pattern (Fig. S7B). Some genes however,
such as the Alzheimer’s disease-associated ELK1, exhibited other patterns
of interaction between fraction and age (Fig. S7C). Expression of ELK1—a
transcription factor that regulates early action gene expression and is impli-
cated in regulating chromatin remodeling, SRE-dependent transcription, and
neuronal differentiation—was increased in adult nuclear RNA compared to
the cytoplasm. In mice, Elk-1 protein abundance is tightly regulated by subcel-
lular compartment as overexpression in the cytoplasm can lead to cell death
(Besnard et al., 2011).
We then assessed fraction- and age-associated genes with brain disease
gene sets for neurodevelopmental, neurodegenerative, and psychiatric disor-
ders curated from many sources, including genome-wide association, copy
number variant, and single nucleotide variant studies33. Neurodegenera-
tive disease genes were enriched for genes that were higher expressed in
cytoplasm in adult cortex (OR=4.3, FDR=1.5e-3), while intellectual disability
genes were enriched for cytoplasmic genes in both ages as well as those only
enriched in adult cytoplasm (OR>2.7, FDR<0.012). Interestingly, genes that
were greater expressed in the nucleus in both ages were enriched for genes
associated with both Autism Spectrum Disorder (ASD; OR>4.9, FDR<4.0e-3;
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Fig S7D), as well as schizophrenia (SZ; OR=6.5, FDR=0.014; Fig S7E). Bipolar
Affective Disorder (BPAD) was also associated with genes greater expressed
in nuclear RNA in adult cortex (OR=3.1, FDR=1.5e-3). Intellectual disability,
neurodevelopmental disorder, and neurodegenerative disorder gene sets were
neither enriched nor depleted for these nuclear-expressed genes. A complete
list of gene sets and enrichment can be found in Table S2.
Because genes with neuronal functions as a group are longer than aver-
age34 and longer genes are more abundant in the nuclear compartment, we
checked if the genes in the disease sets that were over-represented in the
nuclear-enriched genes were longer than other genes. While genes in the four
nuclear-enriched sets (Autism-associated genes from CNV studies, autism-
associated genes from database, schizophrenia-associated genes from CNV
studies, and Bipolar-associated genes from GWAS) were significantly longer
than all other genes (t= 17.6, FDR=3.04e-55), three of the sets were actually
significantly shorter than the genes in the unassociated disease sets (t<-2.7,
FDR<9.5e-03; Fig. 5). Only the autism-associated genes from database were
significantly longer than the other disease genes (t=3.0, FDR=4.1e-03). This
result was probably skewed by the inclusion of TITIN, an almost 118 kilobase
(kb) gene that was 73.3 kb longer than the second longest disease-associated
gene.
2.4 Discussion
Here we have characterized a snapshot of RNA compartmentalization in
developing and mature human postmortem cortex. We find that despite the
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presence of pre-mRNA, the nuclear RNA compartment can be used as an
adequate stand-in for the whole transcriptome when focusing on gene-level
expression. Both nuclear and cytoplasmic RNA captured similar numbers of
differentially expressed genes between developmental stages, and the magni-
tude of change detected was highly correlated between fractions. The use of
PolyA library preparation minimizes the difference between fractions; indeed,
the proportion of splice junctions detected was comparable between fractions
when measured using PolyA libraries, but significantly less in nuclear RNA
when measured with RiboZero.
Interestingly, differences in expression between fractions were much more
muted in prenatal compared to adult cortex. We identified around 63 times
more genes differentially expressed by fraction in adult than prenatal cortex.
Transcription has been shown previously to be more widespread in prenatal
brain than at more mature time points, with 4% of the prenatal genome
transcribed3. We also show that prenatal cortex had a higher proportion of
splice junctions, indicating that the greater volume of prenatal transcription
is being processed. Given that the cellular composition of prenatal cortex
includes a higher proportion of neural progenitor cells and embryonic stem
cells and that these immature cells have a more plastic epigenome35, it is
tempting to speculate that as the brain matures, nuclear retention of RNA
becomes a more utilized regulatory strategy in cells of the brain.
At the gene level, trends in developmental expression patterns support a
down-regulating influence of higher expression in the nuclear compartment.
In adult cortex, being higher expressed in nuclear RNA was associated with
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greater adult expression in nuclear RNA, but greater prenatal expression in
cytoplasmic RNA. Moreover, prenatal-enrichment in cytoplasm was associ-
ated with being greater expressed in adult nuclear RNA, but measured in
nucleus was less expressed in adult nuclear RNA. It is also interesting that 39
of the 40 genes differentially expressed by fraction in prenatal PolyA samples
were higher expressed in nuclear RNA. While this pattern must be tested in
single cell types to be confirmed, it suggests an added layer of regulation to
be considered in the design of next-generation sequencing studies.
IR has been shown recently to be a common splice variant type that in-
creases during development in several cell types including neurons (Mauger,
Lemoine, and Scheiffele, 2016; Wong et al., 2013; Yap et al., 2012). Here we
characterize splicing patterns across fractions in prenatal and adult cortex
and confirm that IR is an abundant splice variant type, particularly in nuclear
RNA. Like overall gene expression, specific splice variants passed more flu-
idly through the nuclear membrane in prenatal cortex than in adult. This led
prenatal-enriched genes to have higher IR ratios than adult in cytoplasm, but
lower IR ratios than adult in nucleus. It is unclear what purpose these in-
trons can be playing in the cytoplasm, although previous work has identified
potential roles as targeting transcripts to dendrites in neurons, or targeting
transcripts for degradation via NMD (Braunschweig et al., 2014; Buckley et al.,
2011). Another curious finding was that nuclear-enriched dIRs in adult were
found preferentially in genes higher expressed in adult rather than in prenatal
cortex. These introns were distributed primarily in the 5’ end of the gene, in
contrast to expectations from previous work that retained introns be toward
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the 3’ end (Braunschweig et al., 2014). Further work in specific cell types or
single cells will be required to resolve these relationships; nevertheless, IR
did link developmental and compartmental expression trajectories in the data,
given that dIRs by fraction were more likely to be differentially retained by
age as well.
By profiling RNA editing across fractions and ages, we confirmed that
RNA editing was not globally associated with RNA localization by fraction,
although we identified many sites that were unique to a fraction in one age
that were found in all samples of that fraction and age group. These unique
editing site groups were found in genes that were more highly edited than
other genes and that were higher expressed in those samples than in the
opposite age or fraction, although almost all edited exons and introns were
present in the other fraction or age in question. The limited read depth in the
samples, however, challenges the RNA editing analysis. Future work that
probes the relationship of these unique sites to localization and expression
should study specific cell types at greater coverage.
Finally, we found that nuclear-enriched genes were also preferentially en-
riched in gene sets associated with neurodevelopmental psychiatric diseases
but not other brain diseases. Previous work has identified the importance of
proper nucleocytoplasmic transport in brain diseases, particularly neurode-
generative diseases such as fronto-temporal dementia and amyotrophic lateral
sclerosis (Mertens et al., 2013; Zhang et al., 2015). Genes associated with these
and related diseases were associated with increased adult cytoplasmic expres-
sion, in line with their important roles in mature cortex. Surprisingly, however,
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we found that genes associated with neurodevelopmental psychiatric diseases
like ASD, SCZ, and BPAD were more likely to have higher expression in the
nucleus in both ages tested, but particularly adult. This association was not
related to neuronal genes being longer and therefore taking more time to leave
the nucleus. This result suggests that these genes may be undergoing extra
processing or regulation in the nucleus that may make them more vulnerable
to dysregulation.
This study is limited by lack of single cell or cell type-specific insight into
these patterns. By using human postmortem brain tissue, we trade improved
clinical validity for reduced resolution of nucleocytoplasmic expression pat-
terns. As mentioned previously, prenatal and adult cortices are populated by
different cell types in different proportions, each with different proliferation,
potency, and connectivity patterns that may influence the import-export de-
cisions across the nuclear membrane. Despite having to average the signal
across cells and cell types, that we still see this association between nuclear-
expressed genes and psychiatric disease genes suggests that further study of
this relationship is warranted.
2.5 Materials and Methods
Post-mortem brain samples
Three prenatal and three adult human postmortem brains were selected from
the collection of the Lieber Institute for Brain Development for use in this
study. Brains in this collection were acquired, dissected, and characterized
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as described previously (Jaffe et al., 2015; Lipska et al., 2006). Briefly, post-
mortem human brain was obtained by autopsy primarily from the Offices
of the Chief Medical Examiner of the District of Columbia and the Com-
monwealth of Virginia, Northern District after informed consent from legal
next of kin (protocol 90-M-0142 approved by the NIMH/NIH Institutional
Review Board). Brain tissue was stored and dissected at the Clinical Center,
NIH, Bethesda, Maryland and at the Lieber Institute for Brain Development
in Baltimore, Maryland. Brain material was donated and transferred to the
Lieber Institute under an approved Material Transfer Agreement. Clinical
characterization, diagnoses, toxicological analysis, and macro- and micro-
scopic neuropathological examinations were performed on all samples using
a standardized protocol approved by the Institutional Review Board of the
University of Maryland at Baltimore and the State of Maryland. Subjects with
evidence of macro- or microscopic neuropathology, drug use, alcohol abuse or
psychiatric illness were excluded.
Cytoplasmic and nuclear RNA purification and
sequencing
A diagram of the study design is included in Fig. S1. Homogenate gray matter
from the dorsolateral prefrontal cortex (DLPFC) approximating BA46/9 in
adults and the corresponding region of PFC in prenatal samples were used
for RNA extraction. To purify cytoplasmic from nuclear RNA, we used the
Norgen Biotek Corp. Cytoplasmic and Nuclear RNA Purification Kit (Cat #
21000, 37400) following the manufacturer’s protocol including the optional
DNase I treatment. RNA-sequencing libraries were prepared from each RNA
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fraction using PolyA-selection ("PolyA"; Illumina TruSeq Stranded Total RNA
Library Prep Kit, Cat # RS-122-2201) and rRNA-depletion ("Ribozero"; Illu-
mina Ribo-Zero Gold Kit (Human/Mouse/Rat), Cat # MRZG126) protocols to
enrich for mRNA species. The resulting 24 libraries were then sequenced on
one lane of an Illumina HiSeq 2000; the Illumina Real Time Analysis (RTA)
module performed image analysis and base calling, and ran the BCL converter
(CASAVA v1.8.2), generating FASTQ files containing the sequencing reads.
"Br5339C1_polyA" and "Br5340C1_polyA" FASTQ files were downsampled
to 24 million total reads to make the read depth more comparable across
samples by joining paired read files, randomly shuffling read order while
maintaining read pairs, and limiting the new downsampled FASTQ file to the
top 12 million read pairs in the file.
Data processing and quality control
Raw sequencing reads were mapped to the hg19/GRCh37 human reference
genome with splice-aware aligner HISAT2 version 2.0.4 (Kim, Langmead, and
Salzberg, 2015), with an average 86.8% alignment rate for PolyA samples
and average 92.6% alignment for RiboZero samples. Feature-level quantifica-
tion based on GENCODE (release 25, lift 37) annotation was run on aligned
reads using featureCounts (subread version 1.5.0-p3) (Liao, Smyth, and Shi,
1900). Exon-exon junction counts were extracted from the BAM files using
regtools (Regtools) v. 0.1.0 and the ‘bed_to_juncs‘ program from TopHat2
(Kim et al., 2013) to retain the number of supporting reads. Annotated tran-
scripts were quantified with Salmon (Patro et al., 2017) version 0.7.2. Finally,
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alignment/processing metrics and the featureCounts results for genes, exons,
exon-exon splice junctions, and annotated transcripts were read in and struc-
tured into analyzable matrices using R version 3.3.1. As a quality control check,
raw FASTQ files were run through FastQC software (Andrews, 2010), and all
samples passed quality statistics including GC content, adapter content, and
overall quality. After pre-processing, all samples passed additional QC checks
for alignment rate, gene assignment rate, and mitochondrial mapping rates.
Gene expression analysis
Principal component analysis was done using the plotPCA() function from
the DESeq2 bioconductor package (Love, Huber, and Anders, 2014) (Fig. 1A).
Read distribution in Fig. S2D was calculated using the read_distribution.py
function in the RSeQC suite (Wang, Wang, and Li, 2012). Annotation features
were assigned in a prioritized order, so that reads overlapping coding (CDS)
exons were labeled first, then untranslated (UTR) exons, then introns, and
finally intergenic regions.
Gene expression differences were measured using the DESeq2 biocon-
ductor package. Samples were segregated by library, fraction and age and
compared using several linear models. Gene expression was first modeled by
library type in the 11 nuclear samples using "∼ Library" (Fig. S2A). To check
localization patterns of known nuclear and cytoplasmic genes, we modeled
"∼ Age + Fraction" separately in the 12 PolyA and 11 RiboZero samples (Fig.
S2B). Adult and prenatal samples from each library separately were assessed
for differential gene expression by fraction ("∼ Fraction"), while nuclear and
56
cytoplasmic samples from each library were separately assessed by age ("∼
Age"), culminating in eight sets of results. These results were reported in Fig.
1B-1C, Fig. 2A-2B, Fig. 2D, and Fig. S3C-S3D.
For subsequent gene expression analyses (i.e., those in Fig. 1D-1E, Fig.
2C-2E, Fig. S2C, and Fig. S3A-S3B), a gene was considered significantly
differentially expressed if the absolute value of the log2 fold change (LFC)
was greater than or equal to one, and if the false discovery rate (FDR) was less
than or equal to 5%.
We subset these genes according to whether they were in agreement across
ages if measuring changes in expression by fraction, or across fractions if
measuring changes by age, resulting in eight groups (e.g., both nuclear, both
cytoplasmic, nuclear in prenatal only, nuclear in adult only, cytoplasmic in
prenatal only, cytoplasmic in adult only, nuclear in prenatal but cytoplasmic in
adult, and cytoplasmic in prenatal but nuclear in adult for comparison of gene
expression by fraction). "Interaction" genes were considered those meeting
the above criteria using the model "∼ Age + Fraction + Age:Fraction" in the
12 PolyA samples.
Gene and disease ontology enrichments were calculated using the com-
pareCluster() function from the clusterProfiler (Yu et al., 2012) bioconduc-
tor package. We used brain disease gene sets from Birnbaum et al. (2014)
and calculated enrichment of these genes within the nine groups of fraction-
associated genes described in the previous paragraph, only without imposing
an LFC threshold of the absolute value of one LFC on the fraction-associated
genes, and filtering disease gene sets for those whose gene symbol were not
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represented in the genes expressed in the dataset.
Splicing analysis
The proportion of splice junctions per sample were calculated by dividing the
number of reads overlapping a known or predicted splice junction by the total
number of reads.
To characterize splice variant type use across the PolyA samples, we used
the SGSeq (Goldstein et al., 2016) bioconductor package. We first extracted
features from the bam files using getBamInfo(), then used analyzeFeatures()
to predict and quantify splicing events in each bam based on GENCODE
(release 25, lift 37). We finally analyzed and summarized that output using
analyzeVariants(), setting the minimum denominator to 10. The number of
unique splice variants of each type were counted by extracting the types using
variantType(). We calculated differential splice variant use by fraction and age
using the DEXSeq (Anders, Reyes, and Huber, 2012) bioconductor package. In
building the DEXSeq dataset, we used the variant IDs as the featureID and the
event IDs as the groupID in the DEXSeqDataSet() function. Similarly to the
gene-level expression analyses, we subset the 12 PolyA samples by fraction
and age and compared differential splice variant expression by fraction using
the full model "∼ sample + exon + fraction:exon" and the reduced model "∼
sample + exon." We compared splice variant expression by age using the full
model "∼le + exon + age:exon" and the reduced model "∼ sample + exon."
We then stratified these results by splice variant type and used Fisher exact
test to calculate the enrichment of each type in each fraction and age.
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To further assess intron retention in the PolyA samples, we filtered in-
trons from the IRFinder-IR-nondir.txt output of IRFinder (Middleton et al.,
2017) run on the Human-hg19-release75 reference for each sample. We ex-
cluded introns with the "NonUniformIntronCover" warning and those that
had anything but "clean" listed in the GeneIntronDetails output column (i.e.,
excluding "anti-near", "anti-over", "known-exon+anti-near", "known-exon",
and "known-exon+anti-near+anti-over"). Introns were further filtered to ex-
clude introns with fewer than four reads spanning the splice junction or a
junction using either the 5’ or 3’ exon-intron boundary, or with fewer than four
reads supporting intron inclusion at each exon-intron boundary. To assess the
relationship between gene expression and IR, we assigned the maximum IR
ratio per sample for each gene from this filtered set of introns and compared
IR ratios of genes regulated by fraction and age (FDR≤.05) using Student’s
t-test and Fisher exact test.
To quantify differential retention of individual introns, we subset the
samples by fraction and age and filtered the IRFinder-IR-nondir.txt output to
create four new lists, first filtering to only include the "clean" introns (from
the GeneIntronDetails output column), then filtering constitutively spliced
introns by group (i.e., adult, prenatal, nuclear, and cytoplasmic). We then used
these new files as input to the analysisWithLowReplicates.pl function from
IRFinder to calculate differential intron retention between fraction in prenatal
and adult, and by age in nucleus and cytoplasm, using the Audic and Claverie
test. We calculated the false discovery rate using p.adjust() and setting the n
parameter to the total number of clean, non-constitutively splice introns in
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each comparison. The relationship between intron retention by fraction and
age and gene expression was further examined by comparing counts of each
using Fisher exact test.
Intron conservation was tested by extracting per base GERP scores for all
"clean" introns from the UCSC Table Browser (hg19), calculating the mean
score per intron, and comparing the means of groups of introns using Stu-
dent’s t-test. Repetitive elements in introns were analyzed by downloading
the RepeatMasker track from the UCSC Table Browser (hg19) and finding
overlaps using findOverlaps() from the GenomicRanges (Lawrence et al., 2013)
bioconductor package.
RNA editing analysis
RNA editing sites were called in the 12 PolyA samples as described previ-
ously18. We annotated the RNA editing sites to genomic features using the
GenomicFeatures50 bioconductor package and a transcription database object
built on GENCODE (release 25, lift 37). Overlap with repetitive sequences
was assessed using the RepeatMasker track downloaded from the UCSC Table
Browser (hg19) by finding overlaps using findOverlaps() from the Genomi-
cRanges50 bioconductor package. We compared the editing sites identified in
this study with previously identified editing sites using findOverlaps(). We
examined the effect of fraction, age, and the interaction of the two on editing
rate in the 1,025 sites present in all samples by first filtering the sites to those
with a finite and non-NA logit-transformed editing rate in at least 5 samples
and with at least one adult, prenatal, nucleus and cytoplasm represented and
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then using the model "∼ Age + Fraction + Age:Fraction." We compared the
pattern of editing in our dataset of the 576 developmentally increasing editing
sites from Hwang et al. (Hwang et al., 2016) present using Fisher’s exact test.
We defined the sets of fraction- and age-specific editing sites by sites
present in all samples of the listed first group that were not found in the
second group. For instance, the "Adult Only" sites were present in all six
adult samples but no prenatal samples. We assigned each editing site to the
nearest gene using distanceToNearest() from the GenomicRanges package and
compared the location of the site by fraction or age with the expression enrich-
ment using the Fisher exact test. We identified KEGG pathway enrichment
using compareCluster() for the ten groups of unique editing sites, setting the
function to "enrichKEGG." Annotation enrichment for these unique sites was
also assessed using the Fisher exact test. To identify the major 3’UTR isoform,
we identified which 3’UTR had the highest read coverage per gene.
We used RBPMap31 to quantify the enrichment of RNA binding protein
(RBP) motifs overlapping the editing sites. We used a region of 10 bases in
both direction of an editing site and the RBPMap database of 114 human RBP
motifs as input, and calculated the false discovery rate using p.adjust() and
setting the n to 2,155,398, or 114 multiplied by the 18,907 A-to-I editing sites
input to RBPMap. The motifs were further filtered to those with FDR≤ 05
that overlap the editing site, and compared to genomic feature annotation
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Differentially Expressed Gene Group Disease Gene Set P-Value Odds Ratio FDR-adjusted
Nuclear: Both ASD.CNV 7.30E-06 7.48 6.57E-04
Nuclear: Both ASD.DATABASE 1.79E-04 4.85 4.02E-03
Nuclear: Both BPAD.GWAS 0.628 1.02 1
Nuclear: Both ID 0.169 2.76 0.802
Nuclear: Both NDD 1 0 1
Nuclear: Both Neurodegenerative 1 0 1
Nuclear: Both SCZ.CNV 1.45E-03 6.46 0.0145
Nuclear: Both SCZ.Meta.analysis 1 0 1
Nuclear: Both SCZ.PGC.GWAS 0.209 2.40 0.907
Nuclear: Both SCZ.SNV 0.683 1.21 1
Cytoplasmic: Both ASD.CNV 0.302 2.84 1
Cytoplasmic: Both ASD.DATABASE 1 0 1
Cytoplasmic: Both BPAD.GWAS 1 0 1
Cytoplasmic: Both ID 1.09E-03 16.10 0.0123
Cytoplasmic: Both NDD 1 0 1
Cytoplasmic: Both Neurodegenerative 0.100 9.81 0.531
Cytoplasmic: Both SCZ.CNV 1 0 1
Cytoplasmic: Both SCZ.Meta.analysis 1 0 1
Cytoplasmic: Both SCZ.PGC.GWAS 1 0 1
Cytoplasmic: Both SCZ.SNV 1 0 1
Nuclear: In Prenatal ASD.CNV 1 0 1
Nuclear: In Prenatal ASD.DATABASE 1 0 1
Nuclear: In Prenatal BPAD.GWAS 1 0 1
Nuclear: In Prenatal ID 1 0 1
Nuclear: In Prenatal NDD 1 0 1
Nuclear: In Prenatal Neurodegenerative 0.0729 13.80 0.416
Nuclear: In Prenatal SCZ.CNV 1 0 1
Nuclear: In Prenatal SCZ.Meta.analysis 1 0 1
Nuclear: In Prenatal SCZ.PGC.GWAS 1 0 1
Nuclear: In Prenatal SCZ.SNV 0.278 3.15 1
Nuclear: In Adult ASD.CNV 0.0112 1.98 0.0843
Nuclear: In Adult ASD.DATABASE 5.40E-04 2.15 7.77E-03
Nuclear: In Adult BPAD.GWAS 3.36E-05 3.14 1.51E-03
Nuclear: In Adult ID 0.661 0.718 1
Nuclear: In Adult NDD 0.710 1.08 1
Nuclear: In Adult Neurodegenerative 0.531 1.44 1
Nuclear: In Adult SCZ.CNV 0.399 1.34 1
Nuclear: In Adult SCZ.Meta.analysis 0.276 1.95 1
Nuclear: In Adult SCZ.PGC.GWAS 0.0112 2.24 0.0843
Nuclear: In Adult SCZ.SNV 2.76E-04 2.32 4.96E-03
Cytoplasmic: In Adult ASD.CNV 0.679 1.11 1
Cytoplasmic: In Adult ASD.DATABASE 0.911 0.949 1
Cytoplasmic: In Adult BPAD.GWAS 9.67E-03 2.00 0.0843
Cytoplasmic: In Adult ID 6.05E-04 2.68 7.77E-03
Cytoplasmic: In Adult NDD 1 0.691 1
Cytoplasmic: In Adult Neurodegenerative 5.15E-05 4.25 1.55E-03
Cytoplasmic: In Adult SCZ.CNV 0.0236 1.89 0.152
Cytoplasmic: In Adult SCZ.Meta.analysis 0.565 1.25 1
Cytoplasmic: In Adult SCZ.PGC.GWAS 0.0155 1.96 0.108
Cytoplasmic: In Adult SCZ.SNV 0.462 0.796 1
Interaction ASD.CNV 0.666 1.32 1
Interaction ASD.DATABASE 0.501 1.32 1
Interaction BPAD.GWAS 0.107 2.69 0.533
Interaction ID 0.212 2.37 0.907
Interaction NDD 1 0 1
Interaction Neurodegenerative 0.0740 4.65 0.416
Interaction SCZ.CNV 0.248 2.13 1
Interaction SCZ.Meta.analysis 0.290 3.00 1
Interaction SCZ.PGC.GWAS 1 0 1
Interaction SCZ.SNV 0.718 1.04 1






























Figure 2.S1: Experimental design We characterized the nuclear and cytoplasmic
transcri tome in huma prenatal postmortem prefrontal cortex (PFC) a d adult
postmortem dorsolateral prefrontal cortex (DLPFC) using two RNA sequencing
library preparation methods. "PolyA" library preparation selects polyadenylated
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Figur 2.S2: Characterizi g the nucle r and cytoplasmic transcriptome in human
brain (A) Differentially expressed genes in nuclear RNA by library type (FDR≤0.05;
abs(Log2 Fold Chang ) ≥ 1). (B) ACTB1, a cytoplasmic gene, and MALAT1, a nuclear
gene, are enriched in the appropriate subcellular fractions. Error bars reflect standard
error. (C) Distribution of lengths of genes enriched by fraction in polyA samples
(FDR≤0.05; bs(LFC)≥1). "Cytoplasmic" and "Nuclear" reflect which fraction in
which the gene is higher expressed, and "Adult" and "Prenatal" represent the age in
which the comparison between fractions was made. (D) Percent of reads mapping to
six genomic features in each group. TES=Transcription end site; TSS=transcription


































































abs(Log2 Fold Change) >1B.	A.	



















































Figure 2.S3: Comparing Fraction and Age in RiboZero Samples (A) Annotation
of groups of genes differentially expressed by fraction in adult and prenatal RNA
(FDR≤0.05; abs(LFC)≥1). The total number in each group is listed to the right of each
bar. (B) Annotation of groups of genes differentially expressed by age in cytoplasmic
and nuclear RNA (FDR≤0.05; abs(LFC)≥1). The total number in each group is listed
to the right of each bar. (C) MA plots of prenatal and adult gene expression differences
measured across fraction. Red dots indicate FDR≤0.05. (D) Log2 fold change (LFC)
of expression across fraction in adult samples plotted against prenatal samples. Black




































Unique Splice Variants by Type

























































Unique Splice Variants by TypeB.	
Figure 2.S4: Overall alternative splicing patterns by splice variant type (A) Counts
of unique skipped exons (SE), skipping of two exons (S2E), intron retention (IR),
mutually exclusive exons (MXE), alternative 5’ exon splice site use (A5SS), alternative
3’ exon splice site use (A3SS), alt rnativ first exon u e (AFE) and alternative last
exon use (ALE) found across all PolyA samples, and the percent of the total they
represent. (B) Counts of unique splice variants of each variant type stratified by
fraction and age. (C) Number of differentially expressed splicing events in different
comparisons, stratified by splice variant type. (D) Volcano plots showing LFC and
âĂŞlog10(FDR) of splicing events stratified by variant type (columns) for different













































































































































































































































































































































Figure 2.S5: Intron retention (A) Quality controls plots showing the number of
intron passing QC (left panel), numb r of genes including an intron passing QC
(middle panel), and the mean sequencing depth per intron (right panel) for each
sample stratified by fraction and age. (B) Density plot of maximum IR ratios per
genes differentially expressed by age measured in cytoplasm (left panel) and nucleus
(right panel) in PolyA samples. Colors are stratified by fraction and age of the sample.
Solid lines indicate genes higher expressed in prenatal cortex, while dotted lines
indicate higher expression in adult cortex. (C) Log2 Fold Change (LFC) of gene
expression by age measured in cytoplasm (left panel) and nucleus (right panel) for
genes containing introns passing QC. The genes are stratified by whether they include
an intron with greater than 0.1 IR ratio or not, and whether the gene is significantly
differentially expressed by age (FDR<0.05). Positive LFC indicates higher expression
in prenatal. (D) Density plots of the location in a transcript of introns higher expressed
in adult and prenatal nucleus (left panel) and introns differentially expressed by age
as measured in both fractions (right panel), listed as the proportion of the transcript


































































Percent of Our Editing Sites Found in Each GTEX Tissue
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Validated Coverage Range By Sample At Edited Sites
A.	
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Number of RNA Editing Sites
 by Feature and GroupB.	 C.	
Age Fraction Interaction
























































































































































































































































































































































































































Figure 2.S6: RNA editing across fraction and age (A) Distribution of filtered read
depth per sample for e h editing contex . "A:G/T:C" sites are considered A-to-
I editing sites in our unstranded RNA-sequencing data. (B) Annotation of RNA
features that contain an A-to-I editing site stratified by fraction and age. Number of
A-to-I editing sites that overlap an Alu sequence, a non-Alu repeat, or no repeats.
(C) Number and percentage of A-to-I editing sites identified in our data that are also
identified in GTEX consortium data. (D) Percentage of editing sites identified in
each GTEX tissue that are also identified in our data. (E) Distribution of unadjusted
p-values calculated from linear regression assessing editing rate changes by age
adjusting for fraction, fraction adjusting for age, or age:fraction interaction effects in
the 1,025 sites found in all samples. (F) Percentage of edited 3’UTRs in each group
of unique editing sites found in all samples in a group that are part of the major

























































ARVCF C15orf59 CACNA1H CCDC64 CNTN3 DMPK GRIK2 LMF2 LZTR1 LZTS2 MBD3 SBF1 SEPT5 SHANK3 TRMT2A TSC2 ZDHHC8















Expression of Genes Associated with AutismD.	
ARVCF C15orf59 CACNA1H CCDC64 CNTN3 DMPK GRIK2 LMF2 LZTR1 LZTS2 MBD3 SBF1 SEPT5 SHANK3 TRMT2A TSC2 ZDHHC8















Expression of Genes Associated with Autism
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Expression of Genes Associated with Schizophrenia
C21orf58 DBNDD1 FBXL19 GOLGA2P5 JAKMIP3 MUS81 TJAP1 WRAP73














Expression of Genes Associated with Bipolar
E.	
F.	
Figure 2.S7: Disease Semantic and Ontology Enrichment (A) Enrichment for dis-
ease ontology terms in "Interaction" genes whose expression varies by both fraction
and age. Th gene ratio for each term is list d in white. (B) ALDH2 gene expre sion
as measured in logarithm of reads per kilobase per million mappe reads plus one
read (log(RPKM+1)), grouped by age (adult (A) or prenatal (P)) and fraction (cyto-
plasm and nucleus). (C) ELK1 gene expression as measured in log(RPKM+1). (D)
Expression of autism-associated gen gre t r xp ssed in ucl than cytoplasmic
RNA in both adult and prenatal cortex. (E) Expression of schizophrenia-associated
genes that are greater expressed in nuclear than cytoplasmic RNA in both adult and
prenatal cortex. (F) Expression of bipolar affective disorder-associated genes that are
greater expressed in nuclear than cytoplasmic RNA in both adult and prenatal cortex.
FDR≤0.05; abs(LFC)≥1. 75
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methylation across human brain
development identifies a unique
role of CpH methylation
3.1 Abstract
We characterized the landscape of DNA methylation across human brain
development in neurons and glia using whole-genome bisulfite sequencing.
We refined global patterns of increasingly divergent neuronal mCpG and
mCpH into six unique developmental trajectories. Within these trajectories,
while mCpH levels remained uncorrelated, together all methylated cytosines
showed similar autocorrelation as mCpG levels alone, unlike across the en-
tire genome. We lastly integrated paired RNA-seq data and identified direct
regulation of hundreds of transcripts and their splicing events exclusively by
mCpH, independent of mCpG levels, across the first decades of human brain
development. We reveal novel insights into the regulation of the neuronal
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epigenome that have significance for human-specific features and neuropsy-
chiatric disease, and a new understanding of the role of CpH methylation in
gene expression.
3.2 Introduction
Neurons are unique cells that function throughout the lifespan, allowing for
an accumulation of programmed developmental changes and experience that
fine-tune neural circuitry in the brain. During development and maturation,
neurons undergo precisely coordinated cascades of genetic regulation that
combine with experience to shape the cellular output via progressive changes
to the epigenome. DNA methylation (DNAm) is an integral facet of the
epigenome that plays a role in establishing cell identity and developmental
trajectories as well as adapting to experience via regulation of gene expression.
Previous large-scale studies of DNAm across human brain development
have been limited to homogenate tissue (Lister et al., 2013) or have used
microarray technologies (Jaffe et al., 2016), creating ambiguity about the
extent of cell type-specific developmental DNAm changes and effects on
transcript isoforms across the genome (Jaffe and Irizarry, 2014). Therefore,
to better characterize the DNAm landscape across human cortical develop-
ment, we performed whole-genome bisulfite sequencing (WGBS, see Meth-
ods) on homogenate tissue and on neurons isolated from 24 human dorsolat-
eral prefrontal cortex (DLPFC) samples aged 0-23 years using NeuN-based
fluorescence-activated nuclear sorting (FANS, Fig. S1A). To complement these
data, we also sequenced 8 FANS-derived glial (NeuN-) postnatal samples
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and 20 homogenate prenatal cortical samples, for a total of 75 samples after
quality control. We fully characterized the landscape of DNAm at both CpG
and non-CpG (CpH) dinucleotides, allowing for a more detailed dissection of
differential DNAm functional specificity. We also sequenced matched tran-
scriptomes of homogenate cortical samples from these donors and a subset of
three nuclear transcriptomes each from neurons and glia isolated by FANS
to assess the functional consequences of epigenomic remodeling. By explor-
ing DNAm patterns in neurons across prenatal and postnatal human brain
development, we reveal novel insights into the regulation of the neuronal
epigenome that have implications for human-specific features and neuropsy-
chiatric disease, as well as a new understanding of the role of CpH methylation
in gene expression.
3.3 Results
After data processing, quality control, and filtering, we analyzed 18.7 million
cytosines in the CpG context at an average coverage of 15x; in agreement with
previous reports (Lister et al., 2013; Schultz et al., 2015; Mo et al., 2015), CpGs
were overall highly methylated (71-76% CpGs>80% methylated, Table S1). De-
velopmental changes in DNAm measured in homogenate cortex were strongly
confounded by developmental shifts in proportion of cell types (OR=7.5, p<10-
100, Fig. S1B). While homogenate measurements were positively correlated
with developmental changes occurring in both neuronal and glial cell types
(ρ=0.79, p<10-100), cell type-specific developmental changes were less con-
sistently observed (ρ=-0.26, p<10-100, Fig. S1C-1E). Overall, roughly 40% of
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cell type-specific developmental DNAm changes could not be detected at all
in homogenate cortex (Fig. S1F), and many of the cell type-specific effects
could not be accurately identified. These results highlight the importance of
measuring DNAm in the appropriate cellular context for improved resolution
in detecting true developmental changes.
3.3.1 DNA methylation and genomic states
Local CpG methylation (mCpG) patterns are known to distinguish specific
genomic states; for instance, so-called unmethylated regions (UMRs) are asso-
ciated with promoters, with subsets of so-called DNAm valleys (DMVs) that
are associated with developmental genes often encoding transcription factors
(TFs) (Jeong et al., 2014; Xie et al., 2013), low-methylated regions (LMRs) often
signify enhancers (Stadler et al., 2011), and partially methylated domains
(PMDs) often associate with heterochromatin and late replicating DNA (Lister
et al., 2009; Salhab et al., 2018; Hovestadt et al., 2014). To better resolve the
developing regulatory landscape in neurons, glia, and bulk prenatal cortex, we
assessed the temporal dynamics of these selected DNAm patterns in the CpG
context. Compared to prenatal and glial cells, neurons experienced a general
accumulation of mCpG 50% faster than the other cells; this was evident in the
LMR and to a lesser extent the UMR landscape, as fewer and smaller regions
were identified across neuronal development (Fig. S2A-B). As expected, LMRs
were highly enriched for transcription start sites (TSSs) and enhancer states in
DLPFC chromatin state data from the Roadmap Epigenomics Consortium (Fig.
S2C) (Consortium et al., 2015). While PMDs are a common feature of most
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cell types, they have yet to be conclusively identified in neurons. Our data
suggested that although the neuronal genome was overall highly methylated,
a small but consistent portion displayed the characteristics of PMDs. We
identified a range of 245 to 404 PMDs per neuronal sample (Fig. S3A) and also
found evidence in an independent WGBS brain dataset (Fig. S3B) (Lister et al.,
2013). PMDs were enriched for heterochromatin, and, interestingly, enhancers
in our postnatal neuronal samples (Fig. S3C). Lastly, we identified signifi-
cant neuronal DMV changes through accumulation of mCpGs that revealed
regulators of cell identity and development and their temporal windows of
expression change (Fig. S4). These data show that neurons and glia undergo
substantial alterations in their DNAm landscape over development in defined
mCpG patterns, including previously unobserved PMD sequence.
3.3.2 Identification of cell type-specific developmentally dy-
namic regions
Given the diverse landscape of methylation features within and across cell
types, we statistically quantified changing mCpG levels by exploiting the
correlation between neighboring mCpGs. We identified 11,179 regions (at
FWER<5%, see Methods) differentially methylated in the CpG context be-
tween cell types; almost all replicated in independent WGBS data (1) (98.4%
concordant, ρ=0.925, Fig. S5A, see Methods), and many overlapped genes
involved in neuronal or glial-specific processes (Fig. S5B). We found fewer
differentially methylated regions (DMRs) for developmental mCpG changes
compared with cell type differences, the majority being within rather than
across cell types (2,178 versus 129 DMRs, respectively, at 5% change in DNAm
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per decade of life, FWER<5%). Among the 2,178 cell type-specific develop-
mental DMRs (cdDMRs), neuronal mCpG patterns again diverged from an
immature landscape shared by glia and prenatal cortex (Fig. 1A). We used k-
means clustering to partition the cdDMRs into six groups with unique DNAm
characteristics (Fig. 1B). 71.1% of cdDMRs fell within groups characterized
by increasing neuronal and/or decreasing glial DNAm over postnatal devel-
opment (Groups 1, 2 and 6). Gene ontology enrichment in the six groups
suggests that these groups are associated with related yet unique biological
roles for the cell types implicated (Fig. 1C). For example, Fig. 1D shows a
Group 6 cdDMR within MBP, a gene encoding a main part of the myelin
sheath created by oligodendrocytes; glia but not neurons progressively lost
DNAm (Lister et al., 2013; Mo et al., 2015), suggesting increased repression
of a non-neuronal fate in maturing neurons not mirrored in glia over post-
natal development in Group 6 cdDMRs. Likewise, the obverse pattern was
observed in a Group 3 cdDMR within presynaptic neuronal gene SNAP25 in
which neurons uniquely and progressively lost DNAm over development (Fig.
1E). We lastly compared these cdDMR groups to a list of putative enhancers
active in human brain development curated by evolutionary age (Emera et al.,
2016) and found strong enrichment for these sequences across all six groups
(Fig. S6A). Human accelerated regions, or conserved sequences that have
experienced rapid mutation in the human lineage (Birnbaum et al., 2014),
were also enriched for dynamic DNAm remodeling (Fig. S6B), suggesting
that our CpG-based cdDMRs may be enriched for sequences related to higher
cognitive functions associated with the human DLPFC.
87
Overlapping cdDMRs with the mCpG features identified above provide
additional context, such as generally scarce overlap with heterochromatic
PMDs, positive correlation of cdDMRs losing neuronal mCpG with increasing
LMR overlap potentially reflecting enhancer element activation during cortical
maturation (Groups 3 & 5 cdDMRs, t>3.8, ρ>0.63, FDR<2.7e-03), and curiously,
a high proportion of cdDMRs gaining DNAm in glia but not in neurons (Group
4 cdDMRs) that overlapped DMVs early in development then steadily lost
overlap in glia (t=-4.3, ρ=-0.87, FDR=1.3e-02, Fig. S7A). Assessing chromatin
state from the homogenate Roadmap Epigenomics brain maps, however,
lacked the resolution to provide this nuance: all six cdDMR groups were
similarly enriched for transcriptional (particularly TSS flanking) and enhancer
chromatin states and depleted for heterochromatin and quiescent states (Fig.
S7B). These results confirm the role of dynamic DNAm in helping establish
epigenomic states that guide cell lineage differentiation and highlight the
utility of creating genome-wide DNAm maps to better parse the functional
diversity of cell type-specific developmental DNAm remodeling in the human
cortex.
3.3.3 Assessing CpH methylation patterns
Unlike many other somatic tissues and cell types, where mCpG is largely the
only context of DNAm, CpH methylation (mCpH) is an abundant, conserved
feature of the neuronal epigenome that distinguishes it from most other cell
types and tissues (Lister et al., 2013; Schultz et al., 2015). We analyzed 58.1
million cytosines in CpH contexts (H=A, T, or C, see Methods), which were
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predominantly lowly methylated (92-99% CpHs<20% methylated). We first
confirmed greater mCpH levels in neurons than glia (7.68M sites, FDR<5%)
that largely increased across postnatal development (3.19M sites, FDR<5%;
Table S2) and were distributed throughout the genome (Fig. S8A). Most
mCpH accumulated in the first five years of postnatal development followed
by a tapered global increase into adulthood, and primarily in either the CAG
or CAC context: overall, total mCAG increased 40% faster than mCAC in
neurons, while glial mCAG accumulated 50% slower than mCAC (Fig. S8B).
However, taking into account relative genome-wide proportions of CAG
and CAC, neuronal mCAG accumulated 30% slower than mCAC (Fig. 2A).
Interestingly, genes that contain significantly differentially methylated mCAC
versus mCAG over development were associated with different biological
processes related to neuronal function and activity, like migration, projection,
and signaling (Fig. S9).
Unlike in the CpG context, where neighboring mCpG levels were highly
correlated, neighboring CpH DNAm levels across the genome were not locally
correlated. However, focusing on cdDMR sequence revealed an interesting
relationship: within cdDMRs, while mCpH levels remained uncorrelated,
together all methylated cytosines (i.e., mCpH + mCpG) showed similar au-
tocorrelation as mCpG levels alone (Fig. 2B). This was especially surprising
given that there were about two times as many mCpHs than mCpGs within
these regions and that the CpG and CpH were relatively interspersed, sug-
gesting functional convergence on the developmentally regulated patterns
identified by mCpG. Indeed, unsupervised hierarchical clustering of CpH
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within the cdDMRs showed infant neuronal mCpH was even more similar to
glia compared to older neurons than mCpG (Fig. 2C). Examining the mean
mCpH compared to mCpG within the k-means cdDMR clusters shows that
the groups gaining mCpG are the most correlated with mCpH trajectories
within the cdDMRs, and that although mCpG is present at high levels pre-
natally, both mCpG and mCpH accumulate at similar rates over postnatal
development in these groups (Fig. S10).
3.3.4 cdDMRs and neuropsychiatric disease
We then examined the relationship between the CpG-based cdDMRs, dy-
namic mCpH sites and human brain disorders, hypothesizing that DNAm
patterns may illuminate the affected cell types and critical risk timeframes
for genomic activity in these complex disorders. Using curated gene sets for
six neurodevelopmental and neurodegenerative brain disorders (Birnbaum
et al., 2014; Psychiatric Genomics Consortium, 2014), we found significant
enrichment exclusively for genes implicated in neurodevelopmental disorders
(e.g. autism spectrum disorder (ASD), schizophrenia, and intellectual disabil-
ity) for many DMR groups, while no DMRs showed enrichment for genes
implicated in neurodegenerative disorders (FDR<0.05). Interestingly, mCpH
differences were depleted within schizophrenia and intellectual disability
genes and were not enriched for any gene set. Cell type DMR enrichment
confirmed neuronal enrichment of schizophrenia risk genes using an orthogo-
nal measurement approach as done previously (Skene et al., 2017). ASD gene
sets were particularly enriched for cdDMRs progressively losing neuronal
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mCpG (Groups 3, 4 & 5) as well as decreasing glial mCpG in Group 6—in
general, for "activating" hypo-DMRs. Two examples are a Group 3 cdDMR
within HDAC4, a calcium-sensitive transcriptional repressor in which neu-
rons progressively lost mCpG after infancy, and a Group 5 cdDMR within
CACNA1B, a calcium voltage-gated channel subunit that lost neuronal mCpG
and gained glial mCpG (Fig. S11). A third example is a Group 6 cdDMR in
AKT3, a serine/threonine-protein kinase gene associated with schizophrenia
that progressively lost mCpG in glia. Given that the most striking shift in
DNAm occurs between birth and five years of age, a period marked by dra-
matic synaptogenesis and the onset of ASD, it is tempting to speculate that
these cdDMRs may be influencing these processes. These results corrobo-
rate previous microarray-based reports, and our WGBS data yielded more
significant effect sizes despite the small number of subjects (Jaffe et al., 2016).
3.3.5 DNA methylation and alternative splicing
Previous studies have shown that both mCpG and mCpH in gene bodies
(particularly in the promoter and first 2 kb) are negatively associated with
gene expression, and that genic mCpH is the most discriminating predictor
of gene expression (Lister et al., 2013; Mo et al., 2015). To anchor our DNAm
patterns in transcriptional activity, we first compared our WGBS data with
NeuN-sorted nuclear RNA-seq data (see Methods) to correlate patterns of
DNAm and gene expression. We took the average DNAm levels across six
biological groups: infant (ages 0-1), child (ages 1-10), and teen (age 10+) within
both cell types individually (neuronal and glial), and calculated associations
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between DNAm and expression (Table S3). Gene expression was negatively
correlated with promoter mCpG regardless of age and cell type (-0.42<ρ<-0.36,
p 0; 57,332 genes). However, only neurons showed a negative correlation
between gene expression and promoter mCpH, a relationship that became
stronger over development (infant: ρ=-0.13 versus child: ρ=-0.23 and teen: ρ=-
0.25). This pattern is consistent with the preferential accumulation of mCpH
in neurons as the brain matures.
Because mCpG has previously been associated with alternative splicing
(Shukla et al., 2011) and mCpH is 15-20% greater in exons than in introns (Lis-
ter et al., 2009), we hypothesized that accumulating mCpH may contribute to
the diversity of alternative splicing characteristic of the brain particularly dur-
ing development. Leveraging our single-base resolution data, we were able to
identify genome-wide functional correlates of mCpH, independent of nearby
mCpG, by associating DNAm with nearby expression in the same cortical
samples. Specifically, we tested whether methylation levels directly associated
with gene or exon expression levels as well as the "percent spliced in" (PSI)
of alternative splicing events using the 22 neuronal samples with matching
homogenate polyA+ RNA-seq data (see Methods). We found 40,940 CpG and
40,303 CpH associations that explain changes in the three expression features
at FDR<5% with a genome-wide p<5x10-4. We further identified 220,622
marginal (p<0.01) CpG associations with expression within 1 kb around the
associated CpH.
While an independent regulatory role of mCpH at the gene and PSI summa-
rizations was rare, there were substantially more exons exclusively regulated
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by local mCpH, largely in the CHH context, in developing neurons (Fig. 3A).
Regardless of context specificity, these regulatory cytosines were depleted in
gene promoters and instead enriched in gene bodies and flanking regions
(Table 1, see Methods). Both contexts were enriched for the high-GC 3’ and 5’
canonical splice site sequence (FDR<1.1e-04), although the associated C could
be either inside or outside the associated expression feature. Most regulatory
cytosines at the gene and exon levels showed significant decreases in expres-
sion as methylation levels increased, and many of these genes were expressed
in a cell type-specific fashion, further justifying the use of homogenate tissue
(Table 1). Although the majority of these DNAm-expression associations were
independent of development despite being identified in developing neurons,
the mCpH changes at these sites were independently associated with age
and expression. Interestingly, many genes, exons, and PSI events associated
with both mCpH and mCpG were also enriched for the neurodevelopmen-
tal disorder gene sets, suggesting that these examples of dynamic isoform
use may be playing a role in the development of higher cognitive functions
associated with the diseases (Fig. 3B). The genes including PSI events regu-
lated by local DNAm levels in both CpG and CpH contexts were consistently
enriched for neuronal components (Fig. S12), while genes with alternative
exons were enriched for synaptic signaling and neurotransmitter transport
(Fig. 3C, full results in Fig S13), suggesting that we are detecting true neu-
ronal mC-expression associations despite measuring splicing in homogenate
RNA-seq.
The associations between these regulatory cytosines and nearby expression
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levels can be explored in a user-friendly webtool
(https://jhubiostatistics.shinyapps.io/wgbsExprs/). Results can be interac-
tively summarized such as in Table 1 for user-selected subsets and visualized
as in Figure 3B or via the UCSC genome browser (Fig. S14). By integrating neu-
ronal mCpG and mCpH levels with accompanying RNA-seq data in the same
brains, we have identified, for the first time, direct regulation of hundreds of
transcripts and their splicing events exclusively by mCpH, independent of
mCpG levels, across the first two decades of human brain development.
3.4 Discussion
This resource of human brain genomics data highlights the dynamic DNAm
landscape of developing cell types and their functional consequences in the
postnatal human cortex. This included the accumulation of mCpG and mCpH
that distinguish infant from more developed neurons across six unique DNAm
developmental trajectories, and the regulatory role of mCpH both in concert
with and independent of mCpG levels in the context of dynamic DNAm
regions and gene expression patterns. The identification of widespread as-
sociation of mCpG and mCpH with expression and specific splicing events,
particularly in neuronal genes enriched for neuropsychiatric diseases, high-
lights a potential novel role of mCpH and further expands the role of mCpG
in the regulation of gene expression in neurons. While this WGBS approach
does not distinguish hydroxymethylcytosine (hmC) from methylcytosine pat-
terns (mC), previous work has shown that only a fraction of CpGs, and no
CpHs, have measurable levels of of 5hmC, suggesting that our results are not
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confounded. Future epigenomics studies of more specific neuronal subpopula-
tions like inhibitory and excitatory neurons can refine the cellular specificity of
these neuronal methylation changes largely occurring in the first few years of
life (Fig. S15). Our data therefore highlight the important regulatory cascades
guiding human brain development using epigenetic mechanisms specific to
neuronal cells, including both mCpG and mCpH.
Data Availability and Materials
Raw and processed data is available from Synapse.org at accession: syn5842535.
Code is available through GitHub at: https:/github.com/LieberInstitute/brain-
epigenomics.
3.5 Materials and Methods
Postmortem brain tissue acquisition and processing
As previously described in Jaffe et al. 2016 (Jaffe et al., 2016), post-mortem
human brain tissue was obtained by autopsy primarily from the Offices of
the Chief Medical Examiner of the District of Columbia, and of the Com-
monwealth of Virginia, Northern District, all with informed consent from the
legal next of kin (protocol 90-M-0142 approved by the NIMH/NIH Institu-
tional Review Board). Additional post-mortem prenatal, infant, child and
adolescent brain tissue samples were provided by the National Institute of
Child Health and Human Development Brain and Tissue Bank for Develop-
mental Disorders (http://www.BTBank.org) under contracts NO1-HD-4-3368
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and NO1-HD-4-3383. Postmortem human brain tissue was also provided by
donation with informed consent of next of kin from the Office of the Chief
Medical Examiner for the State of Maryland (under Protocol No. 12-24 from
the State of Maryland Department of Health and Mental Hygiene) and from
the Office of the Medical Examiner, Department of Pathology, Homer Stryker,
M.D. School of Medicine (under Protocol No. 20111080 from the Western
Institute Review Board). The Institutional Review Board of the University
of Maryland at Baltimore and the State of Maryland approved the protocol,
and the tissue was donated to the Lieber Institute for Brain Development
under the terms of a Material Transfer Agreement. Clinical characterization,
diagnoses, and macro- and microscopic neuropathological examinations were
performed on all samples using a standardized paradigm, and subjects with
evidence of macro- or microscopic neuropathology were excluded, as were all
subjects with any psychiatric diagnoses. Details of tissue acquisition, handling,
processing, dissection, clinical characterization, diagnoses, neuropathological
examinations, and quality control measures were further described previously
(Lipska et al., 2006). Postmortem tissue homogenates of the prefrontal cor-
tex (dorsolateral prefrontal cortex, DLPFC, BA46/9) were obtained from all
subjects.
Fluorescence activated nuclei sorting and NeuN staining
Nuclei were isolated from 100-300mg of pulverized DLPFC tissue using
dounce homogenization followed by ultracentrifugation over a sucrose den-
sity gradient. Homogenization was performed on ice in 5mL lysis buffer
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[0.32M sucrose, 3mM magnesium acetate, 5mM calcium chloride, 5mM EDTA
(ph 8.0), 10mM Tris-HCl (pH 8.0), 0.1% Triton X-100] and the resulting ho-
mogenate was layered over 38mL sucrose buffer [1.8M sucrose, 3mM mag-
nesium acetate, 10mM Tris-HCl (pH 8.0)] and centrifuged at 139,800 x g for
2 hours at 4oC. Cellular debris and lysis and sucrose buffers were removed
and the pelleted nuclei were resuspended in 500uL PBS. Nuclei were then la-
beled in a solution of anti-NeuN antibody conjugated to Alexa Fluor 488 (A60,
Millipore, 1/1000) and 0.1% BSA, rocking for 30 minutes at 4oC, followed by
the addition of DAPI. Nuclei sorting was performed at the the Johns Hopkins
School of Public Health Flow Cytometry Core with a DakoCytomation MoFlo
and data were analysed using FlowJo software (Tree Star).
Nucleic acid extraction and RNA-seq library preparations
RNA was extracted from homogenate and sorted samples using TRIzol LS
Reagent (Thermo Fisher Scientific) followed by the RNeasy MinElute Cleanup
Kit (Qiagen). Genomic DNA extraction was performed using the DNeasy
Blood and Tissue Kit (Qiagen). Bisulfite conversion of 600 ng genomic DNA
was performed with the EZ DNA methylation kit (Zymo Research). RNA
sequencing libraries were made with the TruSeq RNA Library Prep Kit (Illu-
mina) and the RiboGone Low-Input Ribosomal RNA Removal Kit (Clontech).
Library concentrations were measured using a Qubit 2.0 and library fragment
sizes were measured using a Caliper Life Sciences LabChip GX. One hundred
base-pair paired-end sequencing was run on an Illumina HiSeq 2000.
97
Whole genome bisulfite library preparations and sequencing
Sequencing libraries were made with Illumina TruSeq DNA Methylation
library preparation kits. Lambda DNA sequence was spiked in at 1% con-
centration to assess bisulfite conversion efficiency. Library concentrations
were measured using a NanoDrop and library fragment sizes were measured
using an Agilent Bioanalyzer 2100. Libraries were spiked in with 10% PhiX
to improve base calibration calls and subsequently sequenced on an Illumina
X-Ten Platform with paired-end reads (2x150bp), targeting 30x coverage and
Q30 > 70% read quality.
Data processing/alignment
We sought to align the paired-end reads for each sample to the in-silico
bisulfite-treated hg19 genome, which we created using the Bismark v0.15.0
(Krueger and Andrews, 2011) bismark_genome_preparation program. For
each library of paired-end reads (one per sample), the following processing
was performed (Fig. S16):
• FastQC v0.11.4, to assess read quality, presence of adapter sequence, and
overrepresented sequences.
• Trimmomatic v0.35 (Bolger, Lohse, and Usadel, 2014) to trim low qual-
ity and adapter-containing portions of the reads, with the following
parameters: PE -threads 12 -phred33 ILLUMINACLIP:/Trimmomatic-
0.35/adapters/TruSeq3-PE.fa:2:30:10:1 LEADING:3 TRAILING:3 SLID-
INGWINDOW:4:15 MINLEN:75. This resulted in three sub-libraries of
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reads per sample: one paired-end sub-library, and then two single-end
sub-libraries where the other corresponding paired read was trimmed
to a length below the defined threshold.
• FastQC v0.11.4, on each of the three sub-libraries, to assess the improve-
ment in read quality and adapter content following trimming.
• FLASh v1.2.11 (Magoc and Salzberg, 2011), to merge the paired-end
sub-library reads into longer single-end reads, as reads that overlapped
around CpGs and CpHs might bias or at the least double-count the
DNAm estimates. Furthermore Bismark (Krueger and Andrews, 2011)
could only be run on single- or paired-end reads and not a combination
of both. This therefore further split the paired-end sub-library into three
sub-libraries: the subset of paired-end reads that were merged into
longer single-end reads, and then left and right single-end reads that
could not be merged.
• Bismark v0.15.0 (Krueger and Andrews, 2011), to align each of the
five now-single-end sub-libraries (left-trimmed, right-trimmed, FLASh-
merged, FLASh-left-unmerged, and FLASh-right-unmerged) to the bisulfite-
converted hg19 genome using bowtie2 (Langmead and Salzberg, 2012)
and the –non-directional argument.
• Resulting alignment (BAM) files across five sub-libraries were merged,
sorted, and indexed using samtools v1.3 (Li et al., 2009) to produce one
large/merged BAM file per sample.
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• Alignments with evidence of duplication were removed using the MarkDu-
plicates program in Picard tools v1.141, which systematically appeared
to be localized to low complexity DNA sequence near centromeres.
• The Bismark (Krueger and Andrews, 2011) bismark_methylation_extractor
program was run on each post-duplicate-removed BAM file per sample
to extract CpG and CpH DNAm levels.
We additionally aligned reads from each sample to the PhiX and Lambda
genomes to compute quality control metrics related to sequencing and bisulfite
conversion quality. The average percentage of reads mapping back to the
Lambda genome was 1.32% and the average bisulfite conversion efficiency
was 98.64%.
Identifying methylation features
We identified PMDs, UMRs and LMRs using the bioconductor package methylseekR.
We obtained coverage information from the cleaned set of ∼18 million CpGs
by extracting coverage and methylation using the getCoverage() function from
the bsseq bioconductor package. PMDs were called using segmentPMDs()
and were visually inspected using plotPMDSegmentation(). To create a more
stringent cutoff for PMDs, we filtered PMDs to those longer than 100 Kbp.
We calculated the FDRs using calculateFDRs(), while masking the >100 Kbp
PMDs, setting the m parameter to 0.5 and the FDR cutoff to 10. We calcu-
lated UMRs and LMRs using segmentUMRsLMRs(). DMVs were defined
as UMRs in which pmeth was less than or equal to 0.15 and the width was
greater than or equal to 5 Kbp. PMDs were further filtered to exclude overlaps
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with the UCSC "gap" database table from HG19 except for the gaps labeled
heterochromatin.
Identifying CpG differentially methylated regions (DMRs)
Using the bsseq (Hansen, Langmead, and Irizarry, 2012) Bioconductor pack-
age v1.10.0 we loaded the Bismark (Krueger and Andrews, 2011) report files
and filtered the CpG data to keep only the bases where all samples had a
minimum coverage of 3 (18,664,892 number passed the filter). We smoothed
the methylation values of the remaining CpGs using the BSmooth() function
from bsseq with the parallelBy="sample" option. To identify the age and
cell type DMRs we used a model that adjusted for both covariates while for
the interaction model we included an additional interaction covariate. We
identified the DMRs using the bumphunter (Jaffe et al., 2012) Bioconductor
package v1.14.0 using the maxGap=1000, B=250, nullMethod="permutation",
smooth=FALSE options. For the cutoff option we used 0.1 for the cell type
DMRs adjusting for age, 0.005 for the age DMRs adjusting for cell type, and
0.009 for the age and cell type interaction DMRs. We used a family-wise error
rate (FWER) threshold of 5% to determine the DMRs: fwer output from the
bumphunter() function.
Interaction DMRs processing
For the interaction DMRs with FWER<5% we extracted the methylation values
from the glial and neuronal samples using bsseq v1.13.9 (Hansen, Langmead,
and Irizarry, 2012) and then computed a mean methylation value per DMR
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for each cell type. We also calculated the mean interaction coefficient for
each DMR across all the cytosines in the DMR by cell type. Using the mean
coefficients by cell type we clustered the interaction DMRs using the kmeans()
function with centers=6, nstart=100 options. For each cytosine in the inter-
action DMRs we calculated the t-statistic and coefficient for age explaining
differences in methylation adjusted for cell type ("∼ Age + Cell Type"). For
each DMR we computed the mean age coefficient by cell type and then cal-
culated the median absolute coefficient across all interaction DMRs. The
neuronal/glia ratio is 1.5 for such median absolute age effects across the
interaction DMRs.
Comparing homogenate vs. cell type-specific WGBS
We first filtered CpGs to those with coverage in all 55 postnatal samples. For
homogenate samples, we used lmFit() and ebayes() from the limma (Ritchie
et al., 2015) Bioconductor package v3.34.5 to assess age-associated changes
to DNAm levels with the linear model ("∼ Age"). For the cell type-specific
samples, we used a linear model "∼ Age:Cell Type" to assess cell type, overall
age, and age in a cell type changes to DNAm levels. We subset CpGs to
those that were significantly differentially methylated by age in homogenate
samples (p<1x10-4) and plotted the coefficients for each CpG in Fig. S1B, D,E,




We computed the relative enrichments of different genomic regions using
Epigenome Roadmap data (Consortium et al., 2015) by computing the pro-
portion of bases in each of the 15 ChromHMM states for each of the cells
and tissues provided by the Consortium. We compared the proportion of
bases in each state within each candidate region set to the overall genome
and computed the corresponding log2 enrichments between the regions and
this genomic background. We compared DMR and mCpG-based methylation
feature regions to all profiled cell types in the Consortium for these analyses.
Visualizing DMRs
Plots for the DMRs were made using bsseq (Hansen, Langmead, and Irizarry,
2012) v1.14.0, EnsDb.Hsapiens.v75 v2.99.0, and RColorBrewer v1.1-2. Genes
within 20 kb of a DMR were retained for the plots. ATAC peaks (see ATAc-
seq data processing) were included using the addRegions argument of the
plotManyRegions() function from bsseq. Genes and exons were included
using the annoTrack argument and we used extend=2000 for making the
plots.
CpH processing
Using Bismark v0.16.3 (Krueger and Andrews, 2011) we created report files us-
ing the methylation extractor program with the CX_context and split_by_chromosome
options for the hg19 human genome in order to extract the methylation val-
ues for the CpHs. Then for each chromosome, using the bsseq (Hansen,
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Langmead, and Irizarry, 2012) Bioconductor package v1.10.0 we loaded the
Bismark (Krueger and Andrews, 2011) report files and added the c_context
and trinucleotide_context information from Bismark using custom R code
based on the bsseq internal code that uses the data.table package v1.10.4. After
combining the results for each chromosome, we filtered the CpHs to keep only
those where all samples had a minimum coverage of 5 (58,109,566 number
passed the filter).
Lister, et al. data processing
We downloaded the WGBS data from Lister et al. data (Lister et al., 2013) with
SRA accession SRP026048. We then processed and aligned the data following
the same steps we used for our data. Using bsseq (Hansen, Langmead, and
Irizarry, 2012) as in the CpH processing section, we extracted the methylation
values from the Bismark (Krueger and Andrews, 2011) report files and added
the c_context and trinucleotide_context information per chromosome. We
then merged the results for all the chromosomes retaining only the CpG and
CpH positions we observed with a minimum coverage of 3 and 5 in our
data, respectively. To assess the replication of our cell type DMR results we
computed mean methylation differences across the CpG positions comparing
neuron and non-neuron samples in the Lister et al. data (Lister et al., 2013)
using the rowttests() function from the genefilter package version 1.56.0. We
then computed the mean difference for each of the DMRs and compared
this mean difference against the DMR mean methylation difference derived
from our data to derive the concordance and correlation between them. To
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assess the replication of our age DMR results we modeled age as a continuous
variable and calculated the mean methylation difference per year for every
CpG contained in the age DMRs using lmFit() function from limma. Finally,
we compared the mean methylation difference in the Lister et al. data (Lister
et al., 2013) against the observed mean methylation difference for the age
DMRs we derived.
Homogenate data processing
We processed the prenatal and postnatal homogenate brain samples using
the same procedure described in the Data processing/alignment section to
produce Bismark (Krueger and Andrews, 2011) report files. Then using bsseq
(Hansen, Langmead, and Irizarry, 2012) we extracted the methylation values
for the CpG positions observed in our postnatal samples in order to make
them comparable to each other.
Identification of differentially methylated positions
With the set of CpGs and CpHs with a minimum coverage 3 and 5 in all
samples, respectively, and the same models for identifying the DMRs, we
identified the differentially methylated positions (DMPs) keeping the CpGs
and CpHs separate. For the CpHs we further filtered to keep only those
where at least 5 samples had a methylation value greater than 0 (40,818,742,
70.2%). We used the limma Bioconductor package v3.30.13 for determining
the DMPs by running functions lmFit() and eBayes() with default parameters
and FDR<5%.
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Enrichments for genes related in brain disorders
We calculated the relative enrichments of genes overlapping different methy-
lation features with the gene sets described by Birnbaum et al (Birnbaum et al.,
2014). For the genes identified for each disorder, we compared what fraction
overlapped DMRs, and compared these ratio to the rest of the genome using a
chi-squared test. We corrected for testing multiple disorder gene sets using
the false discovery rate (FDR).
Enrichments for regions implicated in HARs and enhancers
We calculated the relative enrichments of genomic segments overlapping
cdDMRs and both human accelerated regions (HARs) and enhancers (Emera
et al., 2016) using chi-squared tests. Here we used the set of CpG clusters used
to identify the DMRs and calculated enrichments of clusters containing both
cdDMRs and HARs.
RNA-seq data processing
Raw sequencing reads were mapped to the hg19/GRCh37 human refer-
ence genome with splice-aware aligner HISAT2 v2.0.4 (Kim, Langmead, and
Salzberg, 2015). Feature-level quantification based on GENCODE release 25
(GRCh38.p7) annotation on hg19 coordinates was run on aligned reads using
featureCounts (subread v1.5.0-p3) (Liao, Smyth, and Shi, 2014). Using custom
R code we processed the different feature counts and created RangedSum-
marizedExperiment objects using the SummarizedExperiment Bioconductor
package v1.4.0.
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Percent spliced in (PSI) calculation
We calculated the percent spliced in using the SGSeq (Goldstein et al., 2016)
Bioconductor package v1.12.0 and the Gencode v25 annotation for the GRCh37
human reference genome (ftp.sanger.ac.uk/pub/gencode/Gencode_human/release_25/
GRCh37_mapping/gencode.v25lift37.annotation.gtf.gz) from the BAM files
generated by HISAT2. We used default arguments except for the function
analyzeVariants() where we used a min_denominator=10.
Differential expression between cell types
We combined the gene counts for the polyA+ and RiboZero sequencing proto-
cols for the cell-sorted RNA-seq data: 3 NeuN+ and 3 NeuN- samples for a
total of 12 RNA-seq sequencing runs. We calculated the library size normaliza-
tion factors using calcNormFactors() from edgeR (Robinson, McCarthy, and
Smyth, 2010) and identified the differentially expressed genes using voom(),
lmFit() and eBayes() from limma (Ritchie et al., 2015; Law et al., 2014). We
repeated this procedure for the exon counts.
Gene ontology analyses
Gene ontology enrichment analyses were performed using clusterProfiler (Yu
et al., 2012) v3.6.0 using the options pAdjustMethod="BH", pvalueCutoff=0.1,
qvalueCutoff=0.05 on the ENSEMBL gene ids for each expression feature for
the BP, CC and MF gene ontologies.
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Methylation vs expression associations
With the sorted RNA-seq data, we computed the average gene expression per
age group (infant, child, teen) and cell type (six groups), and correlated these
values to average DNAm levels in the same groups in both the CpG and CpH
contexts at the gene promoter and body, exon (500bp window), and splice
junction (50bp into each intron) levels.
With the RangedSummarizedExperiment objects with the RNA-seq polyA
homogenate data and the bsseq objects with the CpG and CpH data we de-
termined which CpG and CpH positions explained changes in expression
(RPKM) at the gene or exon level as well as in percent spliced in (PSI). We
retained only the expression and PSI data from the postnatal samples and
matched them by brain identifier to the neuronal methylation data with a
final sample size of 22. We filtered lowly expressed features using the expres-
sion_cutoff() function from the jaffelab package v0.99.18: mean RPKM>0.22
mean for genes, 0.26 for exons. For genes and exons we transformed the
expression values to log2(RPKM + 1) and extracted the raw PSI values. Using
MatrixEQTL (Shabalin, 2012) v2.2 (GitHub b9a9f01 patch) we then identified
the methylation quantitative trait loci (QTL) for the CpG and CpH methylation
data separately using the function Matrix_eQTL_main()function with options
pvOutputThreshold=0, pvOutputThreshold.cis=5e-4, useModel=modelLINEAR,
cisDist=1000. We identified marginal CpG associations near CpH associations
by running MatrixEQTL again for the CpG in a +- 1kb window around the
CpH positions with an association with expression at FDR <5% for each
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expression feature type using the same parameters as above except for pvOut-
putThreshold.cis=0.01. We filtered the associations to retain only those having
at least 11 samples with non-zero methylation and 11 samples with non-one
methylation values to remove extreme cases. We further restricted the results
to protein coding genes and dropped any with infinite t-statistics. To assess
whether age confounds the relationship between methylation and expression,
we used a multiple linear regression model adjusting for age and checked
if the methylation coefficient was still FDR<5%. Venn diagrams in Figure
3 were made with the VennDiagram package v1.6.18. For the gene and PSI
associations we used the gene id to check if it was present in the 3,473 dif-
ferentially expressed genes from the sorted RNA-seq data (described above)
with higher expression in neurons and the top 5,000 DE genes with higher
expression in glia at FDR<5%; similarly we did so for exons and the top 5,000
DE exons (FDR<5%) with higher expression in each cell type. The LIBD WBGS
Expression explorer at https://jhubiostatistics.shinyapps.io/wgbsExprs/ was
made using the bsseq (Hansen, Langmead, and Irizarry, 2012) v1.14.0, DT
v0.4, SGSeq (Goldstein et al., 2016) v1.12.0 and shiny v1.0.5 R packages.
Global autocorrelation
Using CpG and CpH positions with a minimum coverage of 3 and 5 respec-
tively for all samples we calculated the autocorrelation for the methylation
levels for the CpGs, the CpHs, the CpHs with a CHG trinucleotide context, or
the CpHs with a CHH trinucleotide context. For each of the sets, we grouped
the positions using derfinder v1.12.0 into groups by a maximum distance of 1
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kb. Only those groups with at least 5 Cs were further considered. For each
sample we then calculated the autocorrelation using the acf() function with
lag.max=4 in parallel for each chromosome using BiocParallel v1.12.0. For
each cluster of cytosines we calculated the mean across the neuronal (NeuN+)
and the glia (NeuN-) samples at each autocorrelation lag. After combining
and tidying the results, we visualized the global auto correlation using ggplot2
v2.2.1. We repeated this same analysis for the Lister et al. data (Lister et al.,
2013).
Autocorrelation within DMRs
Similar to the global autocorrelation, we extracted the methylation values
at CpGs with a minimum coverage of 3 and the CpHs with a minimum
coverage of 5 that were within each of the sets of DMRs (age, cell type or
interaction). We then computed the autocorrelation for DMRs with a least 5
different cytosines using the acf() function with a lag.max=4 and calculated




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.2: CpH methylation patterns across brain development. (A) Increasing
mCpH in the CAC and CAG trinucleotide contexts in neurons across brain devel-
opment. (B) Autocorrelation levels were similar for mCpG and all cytosines, with
uncorrelated levels in the CpH context. mCpH levels also discriminated older neurons
from both infant neurons and glia within mCpG-based cdDMRs.
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Figure 3.3: Methylation associations with expression. (A) Venn diagrams of the
methylation associations by unique feature for the gene, exon and PSI features. The
sets are determined by whether the association is FDR<5% genome-wide for CpG
and CpH or if it is a CpG marginally significant within +/- 1kb window of a CpH
association. (B) Example associations between methylation and expression at the
gene level with colors by age group: red-infant, orange-child, green-teen, blue-adult.
GUCY1A3 is one of the top CpH that is differentially expressed between neurons and
glia; Expression of an exon within TTN, a gene associated with autism, is negatively
associated with mCpH. Lastly, DOCK1 PSI of an alternative end site is negatively
associated with mCpH. (C) Enriched molecular function ontology terms for exons
associated to methylation by the groups from (A).
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t−statistics for global age vs interaction
Lines at interaction quantile 2.5% and 2


















Figure 3.S1: Gating strategy and comparison to homogenate tissue (A) Represen-
tative gating strategy from fluorescence-activated nuclear sorting by NeuN antibody.
(B) Developmental age effects from homogenate samples compared against cell type
effects at the CpG level, adjusting for age. (C) Developmental age effect from ho-
mogenate samples compared against the developmental effect adjusting for cell type
in sorted samples at the CpG level. (D) Developmental age effect from homogenate
samples compared against the cumulative age and cell type interaction effects in
sorted samples at the CpG level. (E) Developmental age effect from homogenate sam-
ples compared against the estimated cell type specific age effects for sorted samples
at the CpG level. (F) Overall age mean t-statistic for the cdDMRs (x-axis) against the
mean interaction t-statistic (y-axis) with the 2.5% quantile from the y-axis shown on
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.S2: Assessment of Low- and Unmethylated Regions (A) Number of LMRs
identified by age stratified by cell type. (B) Percent of the genome covered by LMRs
by age stratified by cell type. (C) Roadmap Epigenomics Consortium enriched states
for LMRs and UMRs.
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Figure 3.S4: Assessment of DNA methylation valleys (DMVs) (A) Overlap of
transcription factor (TF) genes found in DMVs in each age group. While most TFs
remain in DMVs throughout postnatal development, some become methylated. (B)
DMV gene expression enrichment of genes in a DMV in one age but not the other
listed age group (e.g., "InotC" represents genes genes in Infants but not children
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Figure 3.S5: Extended CpG methylation results (A) Replication of the DNAm dif-
ference at the CpG level between our data and Lister et al. data (Lister et al., 2013).
(B) Enriched biological process ontology terms in the cell-type DMRs.





























































































































































Figure 3.S6: cdDMR enrichment for enhancers and human-accelerated regions
(HARs) (A) Enrichment for enhancers in the six clusters of cdDMRs from Fig. 1B at
the CpG-level stratefied by the epoch in which the enhancers evolved. (B) Enrichment
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Percent cdDMRs Overlapped by Methylation Features
B.	
A.	
Figure 3.S7: Extended cdDMR results (A) Percent of cdDMRs by the k-mean groups
from Fig. 1B overlapped by UMR, LMR, DMV and PMD elements across age. (B)
Roadmap Epigenomics Consortium enriched states for the six clusters of cdDMRs
from Fig. 1B at the CpG-level. 120














Neuron 24 18.7x106 10.10% 13.90% 76.00% 58.1x106 91.60% 8.00% 0.40%
Glia 8 18.7x106 11.10% 17.80% 71.10% 58.1x106 99.40% 0.50% 0.10%
Fetal 20 18.7x106 12.10% 17.30% 70.60% 58.1x106 NA NA NA
Homogenate 23 28.2x106 8.50% 16.90% 73.70% 58.1x106 NA NA NA
Table 3.S1: Global methylation summary Number of cytosines measured and dis-
tribution of methylation by context.
121
Model CpG Context CpH Context
FDR < 0.05 % Significant FDR < 0.05 % Significant
Cell type 4824804 25.80% 7682075 18.80%
Age 536164 2.90% 3194618 7.80%
Cell type:Age 90227 0.50% 76 0%
Age in Neurons NA NA 4020371 9.80%
Table 3.S2: Differential methylation summary mC association with cell type and
age in postnatal cell type-specific samples.
122
Type Location Glia:Child Glia:Infant Glia:Teen Neuron:Child Neuron:Infant Neuron:Teen
CpG Promoter -0.408 -0.417 -0.363 -0.413 -0.418 -0.357
CpH Promoter -0.0434 -0.0217 -0.0383 -0.23 -0.131 -0.249
CHG Promoter -0.046 -0.028 -0.048 -0.2 -0.12 -0.22
CHH Promoter -0.048 -0.015 -0.039 -0.22 -0.13 -0.24
CpG Body -0.205 -0.179 -0.181 -0.27 -0.223 -0.233
CpH Body -0.069 -0.0437 -0.0624 -0.294 -0.168 -0.322
CHG Body -0.054 -0.033 -0.055 -0.25 -0.14 -0.28
CHH Body -0.066 -0.041 -0.057 -0.28 -0.16 -0.31
CpG Exon 0.0508 0.0938 -0.0112 -0.017 0.0369 -0.038
CpH Exon -0.0314 -0.00565 -0.0407 -0.213 -0.103 -0.252
CHG Exon -0.0236 -0.00553 -0.0372 -0.177 -0.0769 -0.219
CHH Exon -0.0447 -0.0147 -0.0484 -0.217 -0.124 -0.249
CpG Junction -0.0582 -0.087 -0.0461 -0.11 -0.124 -0.0501
CpH Junction -0.0324 -0.0311 -0.0265 -0.0866 -0.0609 -0.0804
CHG Junction -0.0218 -0.0116 -0.0213 -0.0764 -0.0579 -0.0836
CHH Junction -0.035 -0.0364 -0.0295 -0.0873 -0.063 -0.0767
Table 3.S3: Methylation-expression correlation summary Correlation between ex-
pression of a feature (location) and DNA methylation by methylation context with




















































































Global Proportion of CpHs Methylated >10%
Total ProportionB.	A.	
Figure 3.S8: Extended CpH methylation results (A) Number of differentially methy-
lated CpHs by cell-type (FDR<5%) across the genome. (B) Proportion of methylated
CpHs by trinucleotide context and cell type over development. (C) CpH-enriched













































regulation of T−helper cell differentiation
microtubule cytoskeleton organization
regulation of T−helper 1 type immune response
fatty acid catabolic process
vitamin transport
long−chain fatty acid transport
digestive system development
sarcomere organization
neural precursor cell proliferation
regulation of calcium−mediated signaling
negative regulation of leukocyte proliferation
retina homeostasis
negative regulation of lymphocyte proliferation
negative regulation of mononuclear cell proliferation
myofibril assembly
negative regulation of immune system process
regulation of stem cell population maintenance
regulation of catenin import into nucleus
neuron projection regeneration









negative regulation of dendrite development
neuron recognition
innervation
regulation of neuron migration
nerve development
establishment of vesicle localization
regulation of synapse assembly



























non−CpG BP Enrichment by Age in Neurons
Figure 3.S9: Biological process gene ontology of mCpH CpH-enriched biological



















































































































































































































































































































































































































































































































































































































































Figure 3.S11: Example cdDMRs that overlap schizophrenia genes Example cd-
DMRs overlapping genes from cluster 3 (HDAC4), cluster 5 (CACNA1B) and cluster
6 (AKT3) from Fig. 1B. Cluster 3 was characterized by static glial and decreasing
neuronal methylation over development, cluster 5 had increasing glial and decreas-
ing neuronal methylation, and cluster 6 had decreasing glial and static neuronal
methylation.
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Figure 3.S12: Cellular component ontology for spliced genes Cellular component
enriched ontology terms for CpGs and CpHs associated with changes in percent
spliced in (PSI).
128
Figure 3.S13: Molecular function ontology for spliced genes Molecular function
enriched ontology terms for the CpHs and CpGs associated with exon expression.
129
Figure 3.S14: Figure S9 caption. Interactive display of the CpHs
and CpGs associated with expression at FDR<5% as shown at
https://jhubiostatistics.shinyapps.io/wgbsExprs/
130
Figure 3.S15: Neuronal subtype enrichment in cdDMRs cdDMRs by clusters from
Fig. 1B overlapping differentially methylated positions (DMPs) in the CpG and CpH
contexts stratified by whether they are more highly methylated in GABAergic or
glutamatergic neurons as defined by Kozlenkov et al. (Kozlenkov et al., 2016).
Figure 3.S16: WGBS data processing pipeline
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The work in this dissertation focused on profiling the transcriptomes and
epigenomes in human cortex and cortical cells from fetal life to the mid
second decade, and examining the regulatory strategies that may govern their
changes.
Chapter 2 focused on RNA subcellular localization patterns in developing
and mature human cortex, characterizing the expression differences between
RNA fractions and how these differences change from prenatal development
to adulthood using RNA sequencing. We found that the nuclear and cytoplas-
mic transcriptomes were more similar in prenatal than adult cortex, suggesting
that there is a freer flow of transcriptional products early in development.
We also found that prenatally enriched genes were higher expressed in adult
nucleus than cytoplasm, suggesting that nuclear enrichment in adult may be
a sign of down-regulated expression of these genes. Interestingly, we found
that genes that were enriched in the nuclear compartment of both prenatal
and adult cortex were also enriched in gene sets associated with autism and
schizophrenia. This is an intriguing result given how little is known about the
137
subcellular localization of RNA species in neuropsychiatric disease; indeed,
most transcriptomic studies are conducted on all RNA in a cell, in which any
subtle change in availability in the cytoplasm for translation will be masked.
We also characterized the ability to detect developmental differences in
gene expression using the nuclear fraction and found that using nuclear
RNA had comparable outcomes to cytoplasmic RNA, despite the differences
in composition between the two compartments. This result is relevant for
studies that use fluorescence activated nuclear sorting for single cell or cell
population-based assays.
This study is limited however by the use of homogenate tissue, which
is confounded both by cell type differences and inter-cell variability. Future
directions for this work could examine the localization of these gene sets using
fluorescence in situ hybridization methods in sections of human postmortem
brain.
In chapter 3, we used whole genome bisulfite sequencing to profile the
DNA methylation landscape at single base resolution in neurons and glia
derived from human postmortem brains spanning the timeframe of brain
development and maturation. We identified six developmental trajectories for
DNA regions of changing CpG methylation, and further characterized CpH
methylation patterns in the context of these dynamic CpG regions. We found
that although neighboring CpH methylation levels are not correlated genome-
wide, within these dynamic regions, all cytosine methylation is correlated,
even including CpH. Perhaps most interestingly, we also characterized the re-
lationship between the methylation of single cytosines and expression of local
138
splicing isoforms, finding that CpH is often associated with alternative splic-
ing patterns, even CpH without a nearby or correlated CpG. This is the first
direct measurement of CpH methylation association with splicing in human
neurons. We also find that both the dynamic regions of CpG methylation and
the splicing-associated cytosines are enriched for gene sets associated with
neuropsychiatric disease, highlighting the importance of understanding these
regulatory relationships to understand the etiology of these disorders. Future
work should probe deeper into this cortical biology, focusing on neuronal
subtypes and examining the effects of known DNA methylation modifiers
such as DNMT3 and MECP2 on RNA splicing patterns.
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